Golgipathies in Neurodevelopment: A New View of Old Defects

Sowmyalakshmi Rasika^{1,2}, Sandrine Passemard^{1,2}, Alain Verloes^{1,2}, Pierre
Gressens^{1,3}, Vincent El Ghouzzi^{1*}

1. PROTECT, INSERM, Université Paris Diderot, Sorbonne Paris Cité, Paris, France

2. AP HP, Hôpital Robert Debré, UF de Génétique Clinique, Paris, France

3. Centre for the Developing Brain, Division of Imaging Sciences and Biomedical
Engineering, King's College London, King's Health Partners, St. Thomas' Hospital,
London, United Kingdom

***Corresponding author:**

Vincent El Ghouzzi

Address: Inserm U1141, Hôpital Robert-Debré, 48 Boulevard Sérurier, F-75019,
Paris, France.

E-mail: vincent.elghouzzi@inserm.fr

Phone: +331 40031973, Fax: +331 40031995

Running Head: Golgipathies and Neurodevelopment

Key words: Golgi apparatus; microcephaly; intellectual disability; neurodevelopment;
trafficking; cell cycle; apoptosis

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Abstract

The Golgi Apparatus (GA) is involved in a whole spectrum of activities, from lipid biosynthesis and membrane secretion to the post-translational processing and trafficking of most proteins, to the control of mitosis, cell polarity, migration and morphogenesis, to diverse processes such as apoptosis, autophagy and the stress response. In keeping with its versatility, mutations in GA proteins lead to a number of different disorders, including syndromes with multi-system involvement. Intriguingly, however, over 40% of the GA-related genes known to be associated with disease affect the central or peripheral nervous system, highlighting the critical importance of the GA to neural function. We have previously proposed the term "Golgipathies" in relation to a group of disorders in which mutations in GA proteins or their molecular partners lead to consequences in terms of brain development, in particular postnatal-onset microcephaly (POM), white matter defects and intellectual disability (ID). Here, taking into account the broader role of the GA in the nervous system, we refine and enlarge this emerging concept to include other disorders whose symptoms may be indicative of altered neurodevelopmental processes, from neurogenesis to neuronal migration, to the secretory function critical for the maturation of postmitotic neurons and myelination.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Introduction

One hundred and twenty years ago, in 1898, Camillo Golgi first published his observations of an "internal reticular complex" that surrounded the nucleus of Purkinje cells in the barn owl cerebellum, using his now eponymous silver reduction method [1]. Despite Golgi's demonstration of his reticular complex is a variety of mammalian cell types in addition to neurons, the very existence of this complex, which we now call the Golgi complex or Golgi apparatus (GA), as an independent and consistent intracellular entity was in doubt for much of the first half of its history, in large part because of its variable morphology and technological and methodological limitations. Also in doubt was what specific role, if any, this strange structure could possibly play. We have known for a few decades now that the GA not only exists but is ubiquitous in all eukaryotic cells, from the yeast upward. However, our views on what it does and how it does it continue to evolve.

The best known and most widely accepted roles of the GA are of course in the biosynthesis of some lipids such as glycolipids and sphingomyelin, and in the processing, sorting, packing, routing and recycling of secretory cargo downstream of the endoplasmic reticulum (ER), roles that are important for cellular and organ function throughout the lifespan. However, the GA plays a number of other roles, many of which are of particular importance during development – it participates in cell division, migration, morphogenesis and growth (all of which involve diverse aspects including intracellular organization, polarity and compartmentalization), as well as apoptosis, autophagy and the stress response. In keeping with these multiple roles, many "GA proteins" are also present in other intracellular compartments and are involved in more than one function, including acting as signaling molecules, rather than acting at a purely structural/mechanical or enzymatic level.

The ubiquitous nature of the GA means that any pathogenic mutation perturbing the function of a GA protein could and mostly does result in clinical repercussions across multiple tissues and systems. Strikingly, of the mutated GA-associated genes identified in various monogenic disorders so far, over 40% affect the normal development or functioning of the central or peripheral nervous system, a far greater proportion than for any other tissue type [2], highlighting its crucial roles in different types of neural cells. Indeed, the magnitude of this impact on the nervous system structure and physiology and on neurodevelopment in particular should not be surprising, when one considers the intensive use that neurons and glia presumably make of the GA – in the intricately coordinated processes involved in progenitor cell organization, orientation and mitosis; the subsequent highly directional migration of young neurons to their target regions; the exponential increase in surface area and thus of the biosynthesis of both membrane lipids and proteins required by diverse processes such as dendritic arborization in neurons and myelin sheath production in oligodendrocytes; the heavy demands of synaptogenesis and synaptic and neurosecretory activity, etc. The existence of Golgi outposts in dendrites is a prime example of the adaptation of the GA to the highly compartmentalized nature of the nervous system and its specific trafficking needs (reviewed in [3,4]).

Intriguingly, during the course of our identification of the causal gene and molecular mechanisms underlying Dyggve-Melchior-Clausen (DMC, MIM #223800) syndrome, a disorder in which skeletal defects are associated with a characteristic neurological profile combining postnatal-onset microcephaly (POM), white matter deficits and intellectual disability (ID) [5], we noted the presence of the same combination of symptoms in several other monogenic disorders, each of which was linked to a defect in a gene involved in the GA trafficking machinery. This common profile indicated a similar pathophysiology – defective

1 neuronal or oligodendrocytic maturation at the post-mitotic stage, thus leading to symptoms
2 later during neurodevelopment than in the primary or congenital microcephalies, which result
3 principally from proliferation deficits. Additionally, several of these newly or previously
4 identified disorders appeared to involve a mutation in a GA-associated member of the small
5 RAB GTPase family, which are involved in a plethora of trafficking functions in the cell, or in
6 molecules that interact with the RABs, including their direct effectors and modulators such as
7 the guanine nucleotide exchange factors – GEFs – which activate them by replacing GDP by
8 GTP and allowing them to bind specific effectors, or the GTPase activating proteins – GAPs,
9 which dissociate the active complex. These observations prompted us to propose the term
10 "Golgipathies" or "Golgipathic microcephalies" to designate this emerging class of disorders
11 characterized by a similar phenotype (POM, white matter deficits, notably an abnormal corpus
12 callosum, and varying degrees of cognitive impairment), and caused by mutations in RAB
13 GTPases or their molecular partners [4]. However, an examination of the literature and recently
14 published studies provides ample evidence that defective GA proteins and processes are linked
15 to a wide spectrum of neurodevelopmental defects in addition to the combination that first drew
16 our attention. Not only are there a large number of isolated reports of POM related to GA- or
17 RAB-associated mutations, but a number of other disorders, including several characterized by
18 congenital microcephaly, could also justifiably be classified as Golgipathies, based on the fact
19 that the primary pathogenic mechanism in all of them is a defective GA protein, regardless of
20 its intracellular function (GA structure or intracellular organization, trafficking machinery in
21 the anterograde or retrograde directions, post-translational modifications, cell-cycle
22 involvement...). In light of these new insights, we would like to refine the notion of
23 Golgipathies, taking into account their major neurodevelopmental involvement, with a brief
24 discussion of the relationship between these disorders and the possible GA functions affected.

Golgipathies: more microcephalies and more than microcephalies

Despite their great variety, Golgipathies with a neurodevelopmental component also show considerable overlap and a number of unifying features. Some of these putative neurodevelopmental Golgipathies are described below, grouped according to their principal clinical signs (presence or absence of microcephaly and its onset), and the probable function or position in the trafficking pathway of the affected protein, in order to stimulate discussion as to their potential classification. We have excluded cancer-related GA genes/proteins or those involved in primarily neurodegenerative processes.

I. POM Golgipathies related to RAB GTPases and their molecular partners:

Perhaps due to the fact that most important and "permanent" functions of the GA is that of lipid and protein trafficking, crucial throughout the lifespan of the cell, the POMs constitute a disproportionately large group of Golgipathies affecting neurodevelopment. While many involve other organs and tissues and show remarkable differences in phenotype between one individual and the next, for the purposes of this review, we will concentrate on the neurological aspects (summarized in **Table 1**).

Dyggve-Melchior-Clausen syndrome (DMC; MIM #223800), which first prompted our speculation about Golgipathies as a class of disorders, is an autosomal recessive skeletal dysplasia associated with POM and ID, and caused by loss-of-function mutations in the *DYM* gene encoding DYMECLIN, a GA protein involved in intracellular trafficking [6-8]. Brain MRI reveals a marked thinning of the corpus callosum and brain stem, supported by significant deficits in the volume and structure of myelin in *Dym*^{-/-} mutant mice [5] *Dym*-deficient neurons display a fragmented GA and impaired ER-to-GA trafficking [5], but *Dym* may also

play a role in the retrograde transport of vesicles from the GA to the ER [7]. Several lines of evidence suggest that it has a tethering role during vesicle trafficking between the ER and the GA [6,7] in conjunction with the golgin GINTIN and interactions with RAB1 or RAB6, the most abundant type of RAB [9-11]. Interestingly, *Smith McCort dysplasia*, a clinical variant of DMC syndrome with identical skeletal defects but normal intelligence and no microcephaly, has been found to result either from specific missense mutations in *DYM* that could result in some residual activity of the protein (SMC1; MIM #607326) [6,12] or from loss-of-function mutations in the RAB33B GTPase, also localized in the GA (SMC2; MIM #615222) [13,14].

Warburg-Micro syndrome (WARBM1-4; MIM #600118, #614225, #614222, #615663) is an autosomal recessive disorder [15] characterized by neurodevelopmental defects including POM with profound ID, and progressive limb spasticity associated with progressive peripheral axonal neuropathy [16], severe visual impairment and hypogonadism. Brain MRI shows bilateral frontal polymicrogyria and hypoplasia of the corpus callosum and cerebellar vermis [17,18]. Loss-of-function mutations in four distinct genes, *RAB3GAP1*, *RAB3GAP2*, *RAB18* and *TBC1D20*, have been implicated in WARBM [18-20]. RAB18 has recently been confirmed to localize in the ER and the *cis*-Golgi compartment [21], in addition to other compartments. While TBC1D20 acts as a GAP for RAB18, in addition to acting on ER-localized RAB1 [22] the RAB3GAP complex in this context acts not as a GAP but as a GEF for RAB18 [23]. In the related *Martsolf syndrome* (MIM #212720), only *RAB3GAP2* mutations have been identified, but most patients also display severe neurodevelopmental defects including POM and white matter defects (where examined), ID, hypogonadism and ocular defects [19,24,25].

Mutations in *COL4A3BP* (collagen 4A3 binding protein, also known as Goodpasture antigen binding protein, GPBP, or ceramide transporter, CERT) lead to an *autosomal dominant mental retardation* (MRD34; MIM #616351). The COL4A3BP protein is thought to mediate ER-to-GA transport of ceramide, an essential lipid component. One of the first patients

identified with a mutation in this gene presented with POM in addition to other neurological and skeletal defects [26].

Autosomal recessive mental retardation 13 (MRT13; MIM #613192) is linked to loss-of-function mutations in *TRAPPC9*. Initially considered a nonsyndromic autosomal recessive ID [27-29], with additional cases, MRT13 is beginning to show a fairly distinctive phenotype, including moderate to severe POM, a peculiar facial appearance, obesity and hypotonia. MRI reveals a reduction in cerebral white matter with a marked thinning of the corpus callosum [30-32]. TRAPPC9 is a subunit of the Trafficking Protein Particle (TRAPP) complex that mediates the tethering of COPII-coated ER-derived vesicles to *cis*-Golgi membranes [33]. The TRAPP complex acts by activating RAB1, which in turn recruits specific *cis*-Golgi effectors such as the golgins P115 and GM130 to allow vesicle tethering [34]. The TRAPP complex and TRAPPC9 in particular are also involved in the interaction between COPII-coated vesicles and the microtubule motor protein dynactin 1 (DCTN1, equivalent to the *Drosophila* p150^{Glued}) [35].

Progressive childhood encephalopathy (PEBAS; MIM #617669), also linked to mutations in a TRAPP subunit, TRAPPC12, has been identified in 2 families as being linked to progressive microcephaly (including one case of POM), agenesis of the corpus callosum and other MRI abnormalities, and severe developmental delays [36]. Mutations in another TRAPP subunit, TRAPPC6B, have also been linked to a POM syndrome (NEDMEBA; MIM #617862) in several families in a recent report [37].

In Takenouchi-Kosaki syndrome (TKS; MIM #616737), caused by mutations in the GTPase CDC42, which regulates bidirectional Golgi transport by regulating the cargo sorting and carrier formation functions of COPI [38], affected patients show a range of phenotypes affecting different organs, including ID and either POM or congenital microcephaly (reviewed in [39]).

A neuromuscular syndrome with microcephaly noticeable from the 4th postnatal month has been described in an individual who also displayed developmental delays, seizures, hypotonia and muscular dystrophy [40]. Brain MRI revealed delayed myelination and thinning of the corpus callosum. The molecular cause was a loss of function of the *GOLGA2* gene (MIM #602582), which encodes GM130, a multifunctional golgin involved in both the assembly/maintenance of GA structure and the regulation of the secretory pathway and vesicle tethering to the *cis*-Golgi compartment through interactions with RAB1B, P115 etc.; GM130 also binds to other RAB proteins involved in membrane traffic regulation at the ER/Golgi interface, such as RAB2 and RAB33B [41-43].

Autosomal recessive mental retardation 61 (MRT61; MIM #617773), also called Alwadei syndrome, is a POM syndrome that includes profound ID, epilepsy in two cases and a thin corpus callosum [44]; it has been found to be caused by mutations in IPORIN (MIM #617773), a protein encoded by the *RUSC2* gene. Little is known about the RUSC2 protein except that it is ubiquitous and highly expressed in the brain, and interacts with both RAB1B and possibly directly with GM130 [45].

Cohen syndrome (COH; #MIM 216550) is an autosomal recessive disorder characterized by motor delays, progressive retinal dystrophy and severe myopia, hypotonia, joint hypermobility and progressive POM associated with ID [46], associated at times with non-neurological signs [47]. Brain MRI reveals a relatively thicker but more compact corpus callosum in some patients, associated with markedly smaller sagittal diameters of the brain stem [48]. *COH1*, the only gene associated with Cohen syndrome so far, encodes the vacuolar protein-sorting protein VPS13B, a large peripheral membrane protein that is actively recruited at the GA by RAB6 [49,50]. VPS13B likely plays a specific role in the dynamics and function of the GA, in particular during neuronal maturation.

Progressive Cerebello-Cerebral Atrophy type 2 or Ponto-Cerebellar Hypoplasia type

2E (PCCA2/PCH2E; MIM #615851) is an autosomal recessive neurodegenerative disorder characterized by normal development during the initial months of life, followed by motor delays, progressive POM, progressive spasticity and epileptic seizures by two years of age [51]. Brain MRI reveals a gradual decrease in cerebral white matter associated with delayed myelination and thinning of the corpus callosum [51]. The responsible gene encodes VPS53, another vacuolar protein-sorting protein that participates in the transport and recycling of endosome-derived transport vesicles [52]. VPS53 is part of two large multisubunit complexes named Golgi-associated retrograde protein (GARP) and Endosome-associated recycling protein (EARP), that ensure the proper tethering between endosomes and their acceptor compartment [53,54]. Both complexes cooperate with SNAREs for subsequent membrane fusion. GARP has been found to interact with RAB6A at the TGN [55] and EARP associates with RAB4-containing vesicles [54]. A previously unknown neurodevelopmental disorder linked to a mutation in yet another GARP/EARP subunit, VPS51, also appears to exist, based on our own observations (case report in preparation) as well as a BioRxiv description of a 6-year-old patient with severe global developmental delay, pontocerebellar abnormalities, microcephaly, hypotonia, epilepsy and several systemic and peripheral dysfunctions (BioRxiv 409441, 2018).

A pontocerebellar hypoplasia caused by TBC1D23 mutations (PCH11; MIM #617695)

has been shown in two different reports to be associated with POM or microcephaly of unknown onset, along with various other neurodevelopmental deficits and neurological signs (including a hypoplastic corpus callosum, as seen in several Golgipathic POMs, severe cognitive delays, motor weakness or lack of motricity, behavioral problems etc.) [56,57]. TBC1D23, like TBC1D20 in Warburg-Micro syndrome, appears to be a RAB GAP (although neither its GTPase activity nor its RAB specificity has been clearly evidenced so far). It is localized at the *trans*-Golgi and regulated by the small GTPases ARL1 and ARL8, and appears to mediate the binding of endosomal vesicles to golgin-245 and golgin-97 on *trans*-Golgi

membranes to mediate retrograde transport [58]. It has been implicated in the regulation of neuronal migration/positioning during corticogenesis, as well as neurite/axon differentiation [56].

Autosomal recessive periventricular heterotopia with microcephaly (ARPHM; MIM #608097) has been described in several patients to be caused by *ARFGEF2* mutations. The microcephaly in these reports is progressive postnatally in three reports [59-61] and of unknown onset/progression in one [62]. The patients also display severe developmental delays and ID, epilepsy, brain atrophy and myelination delays associated with a thin corpus callosum. *ARFGEF2* encodes BIG2, a GA protein responsible for interior membrane trafficking in the *trans*-Golgi network and endosomes [63]. BIG2 interacts with RAB11, a *trans*-Golgi protein involved in diverse functions such as synaptic transmission, but also neuronal migration and axonal growth, functions that could explain the phenotypes seen in the reports above [64,65].

MEDNIK syndrome (MEDNIK; MIM #609313) is caused by mutations in *AP1S1*, a subunit of one of the five adaptor protein complexes (AP1-5), located at the *trans*-Golgi and in endosomes, that match cargo molecules, including neurotransmitters (and in the case of AP1S1, specifically, the copper pumps ATP7A and B) to their carriers (reviewed in [66]). Symptoms of MEDNIK syndrome, although predominantly cutaneous, include POM in addition to other typical neurological signs such as moderate to severe ID and deafness [67]. Montpetit and colleagues also mention the occurrence of peripheral neuropathy and microcephaly in the original French-Canadian cohort, without indicating age of onset, when discussing their animal model [68], although the original article by Saba and colleagues and subsequent discussions of this cohort only mention brain "atrophy" [67-69]. In addition, mutations in *AP1S2* cause Pettigrew syndrome (PGS, MIM #304340), an X-linked disorder characterized by ID, seizures, Dandy-Walker malformation and microcephaly, possibly postnatal, although head circumference was variable in the original family [70,71].

COG-associated Congenital Disorders of Glycosylation (CDGs) represent one subgroup of a very large family of multisystemic autosomal recessive pathologies involving dysfunctions in the processing of N- and O-linked glycans. While most of the mutations identified so far involve genes encoding glycosylation enzymes [72], the CDGs described in this paragraph are caused by defects in one of the 8 subunits of the Conserved Oligomeric Golgi (COG) complex, localized to the *cis*- and medial-Golgi as well as surrounding vesicles [73]. The COG complex is thought to act as a tethering factor, in particular during intra-GA and retrograde GA-to-ER trafficking, where it mediates the recycling of glycosyltransferases [74], suggesting that the incidence of CDG when COG subunits are mutated is likely due to the inability of these glycosylation enzymes to reach their target proteins [73]. COG-associated CDGs are associated with multiple neurological manifestations, including POM in patients carrying mutations in *COG1* (MIM #611209), *COG2* (MIM #617395), *COG4* (MIM #613489), *COG5* (MIM #613612), *COG7* (MIM #608779) and *COG8* (MIM #611182) [75-81]. Brain MRI has revealed hypoplasia of the corpus callosum in four patients [77,78] and brainstem atrophy in one case [75]. *COG6* mutations have also been associated with borderline POM in Shaheen syndrome (SHNS; MIM #615328) as well as a CDG with congenital microcephaly (MIM #614576) [82,83]. Interestingly, the COG complex has been shown to interact with molecules at all levels of GA organization and trafficking as well as a number of GA-associated RABs (see [4] for an overview).

Another family of GA-associated proteins whose mutation gives rise to a wide range of CDGs with neurological phenotypes is the solute carrier family 35 (SLC35), whose members carry a variety of molecules, mostly sugars, to the GA for the glycosylation of proteins. Mutations in *SLC35A3* have been associated with POM and ID [84] in a syndrome characterized by arthrogryposis, mental retardation and seizures (AMRS; MIM #615553). Similarly, mutations in *SLC35C1* give rise to CDG2C (MIM #266265), in which severe ID and POM have also been noted [85], while mutations in other family members give rise to various

CDGs with ID, microcephaly of unknown onset, and other neurological manifestations (e.g. SLC35A1: CDG2F, MIM #603585; SLC35A2: CDG2M, MIM #300896).

Among CDGs caused by a defective trafficking mechanism, rather than an enzymatic or metabolic deficiency, and including POM, psychomotor delays and white matter abnormalities among their clinical signs, should be included CDG2K, caused by mutations in the transmembrane GA protein TMEM165 (MIM #614727). While the exact function of this protein is not yet known, it is probably an ion transporter that plays a role in pH, calcium or manganese homeostasis, and mutations also appear to affect GA morphology [86,87].

II. Other microcephalies or macrocephalies related to impaired GA function

A number of other reports of patients with microcephalies linked to mutations in GA-associated proteins exist in the literature. However, data on whether these microcephalies are congenital or postnatal (or congenital but progressive after birth) is not always available. Further studies might well turn up other syndromes where a POM or a progressive worsening of microcephaly would indicate a defect in maturation (including trafficking or biosynthetic defects) or other processes that take place later in development, such as gliogenesis, as opposed to a congenital microcephaly that would indicate a deficit in the production of new neurons earlier in development, even though these different microcephalies are likely to lie along the same continuum rather than being mutually exclusive. The other side of the coin is that mutations in several GA-related proteins appear to result in macrocephaly, possibly indicating an opposite effect on the regulation of neurogenesis or neuronal apoptosis during maturation. A few examples of these other microcephalies and macrocephalies linked to GA protein mutations are given below (summarized in **Table 2**).

Mutations in the *WDR62* gene, which codes for a WD40 repeat protein highly expressed in the developing brain, cause autosomal recessive primary microcephaly (MCPH2; MIM #604317) with seizures and ID in addition to congenital microcephaly [88,89]. Interestingly, even though it is best known for its presence at the centrosome during mitosis and appears to play a critical role in neuronal progenitor proliferation during corticogenesis, WDR62 also associates with GM130 and is localized at the GA during interphase, where its function is unknown [89].

Mutations in TRAPPC11, a subunit of the TRAPP complex that plays a role in ER-GA trafficking and activates several RABs, as described above, lead to a limb girdle muscular dystrophy (LGMDR18; MIM #615356) with microcephaly of unknown onset, myopathy, infantile hyperkinetic movements, ataxia, and ID [90,91].

A microcephalic dwarfism syndrome (SRMMD; MIM #617164) characterized by, in addition to microcephaly, facial dysmorphism, severe micrognathia, rhizomelic shortening and mild developmental delay has been associated with heterozygous mutations in *ARCNI* [92]. *ARCNI* (*COPD*) encodes Archain 1, the delta subunit of the vesicular coat protein COPI, necessary for both intra-GA and GA-ER retrograde transport, and ARCN1 haploinsufficiency leads to COPI-mediated transport defects. In addition, a hypomorphic missense mutation in the *COPB2* gene, encoding the beta subunit of COPI, has also recently been found to be the cause of a primary autosomal recessive microcephaly (MCPH19; MIM #617800) in which the congenital microcephaly is associated with severe developmental delay, cortical blindness and spasticity [93]. *COPB2* appears to be involved not only in retrograde GA-ER transport, possibly interacting with DYMECLIN [7], but in early neuronal proliferation and apoptosis [93].

A PEHO (progressive encephalopathy with edema, hypsarrhythmia and optic atrophy) - like syndrome (PEHOL; MIM #617507) caused by a mutation in the *CCDC88A* gene coding

for GIRDIN, a coiled-coil GA protein, shows, in addition to profound psychomotor delay, seizures and progressive brain atrophy, severe congenital microcephaly in all patients, and dysmyelination in one case [94]. GIRDIN, also known as KIAA1212, appears to be involved in the migration and positioning of new neurons, controlling soma size and dendritic branching [95].

AP4-deficiency syndrome is caused by a mutation in a subunit of another of the five adaptor protein complexes, AP1-5, mentioned above (reviewed in [66]). AP4-deficiency syndrome, which includes a very large range of phenotypes, may be included among the large number of hereditary spastic paraplegias [96]. Among them, *AP4E1* mutations (MIM #613744) lead to a form of hereditary spastic paraplegia with congenital microcephaly, ID, thin corpus callosum, psychomotor deficits and spasticity [97-99], which Moreno-de-Luca and colleagues found to be similar to another hereditary spastic paraplegia caused by mutations in *AP4M1* (MIM #612936), in which several patients displayed microcephaly in addition to other neurological signs [100]. Similarly, Abou Jamra and colleagues also found microcephaly, along with a variety of other symptoms in patients with *AP4B1* (MIM #614066) and *AP4S1* mutations (MIM #614067) [97]. Surprisingly, microcephaly of unknown onset associated with ID has also been noted in Hermansky-Pudlak syndrome 2 (HPS2; MIM #608233), not commonly thought to be associated with neurodevelopment; in this disorder, mutations in *AP3B1* principally lead to oculocutaneous albinism, immunodeficiency and hematological abnormalities [101].

As in the case of the TRAPP and AP protein families, mutations in another SLC family member, SLC9A6, are also associated with other forms of microcephaly (congenital, progressive, or of unknown onset) and severe ID in the X-linked mental retardation known as Christianson syndrome (MRXSCH; MIM #300243) [102-104].

In an early infantile epileptic encephalopathy (EIEE49, MIM #617281) caused by mutations in *DENND5A*, a gene encoding a GA-localized GTPase activator thought to play a

role in neuronal differentiation, almost all affected individuals show microcephaly in addition to various other neurological signs, including seizure onset in the neonatal period, global developmental delay with ID and lack of speech, hypotonia, spasticity etc. [105,106]. DENND5A acts as a GEF for the neuronal GA-specific GTPase RAB39 [107], which is involved in regulating the number and morphology of neurite growth cones and in synapse formation and maintenance, including alpha-synuclein homeostasis. However, deficits in RAB39B are also associated with an X-linked form of ID with macrocephaly rather than microcephaly (MRX72; MIM #300271) [108,109]. Macrocephaly is also a feature of RAB39B-associated early-onset Parkinsonism or Waisman syndrome (WSMN; MIM #311510) [110,111].

Mutations in another GTPase activator, HERC1, which is localized to the cytoplasm and GA/vesicular compartments and acts as a GEF for ARF1, and possibly RAB3A and RAB5 [112], also result in a macrocephaly syndrome with dysmorphic facies and psychomotor retardation (MDFPMR; MIM #617011) [113-115].

Similarly, in autosomal dominant mental retardation 48 (MRD48; MIM #617751) mutations in the gene encoding the small Rho GTPase RAC1, which appears to interact with various GA proteins and to play a distinct role in neuronal progenitor proliferation, lead to ID with either microcephaly or macrocephaly, as well as a developmental delay, seizures, absent speech and a number of defects on MRI [116]. Interestingly, *SPATA13* (also known as *ASEF2*), encoding a GEF for both RAC1 and CDC42 (involved in Takenouchi-Kosaki syndrome, as mentioned above) that is enriched in the prenatal frontal cortex and plays a role in dendritic spine formation and cell migration, possibly by regulating actin cytoskeletal remodeling [117,118], is among a set of 26 newly identified ID genes [119].

Another GA-associated gene implicated in corticogenesis is the gene for the pseudokinase STRADA (also known as STE20 related kinase adaptor alpha, or LYK5),

deletions in which give rise to macrocephaly in a syndrome encompassing polyhydramnios, megalencephaly and symptomatic epilepsy (PMSE; MIM #611087) [120,121]. STRADA appears to form a complex with STK25 and the golgin GM130 to regulate GA morphology and positioning, thus controlling neuronal differentiation and integration during development [122].

III. GA protein mutations associated with other neurodevelopmental anomalies

Not all GA proteins appear to be associated with microcephalic or macrocephalic syndromes when mutated. However, a number of GA proteins do have other significantly neurodevelopmental effects involving either the central or peripheral nervous system, and lead to phenotypes that include ID, ataxias, peripheral neuropathies or sensorineural loss. Some of these are described below, and also summarized in **Table 3** (excluding GA-localized enzymes whose role lies primarily in protein or lipid biosynthesis/modification, and that are thus likely to have metabolic effects rather than mechanistic ones).

Many GA proteins other than those described in Sections I and II above are implicated in various forms of ID, even without being associated with microcephaly or macrocephaly. For example, mutations in the RAB-GDP dissociation inhibitor GDI1 are responsible for a non-syndromic X-linked form of ID (MRX41/MRX48; MIM #300849) [123-125].

A non-RAB molecular partner of BIG2 (*ARFGEF2*), which, as we have discussed above, causes a periventricular heterotopia and progressive microcephaly, is another GA protein, FILAMIN alpha (FLNA), that plays a role in neuronal migration by regulating the relocalization of BIG2 and the activation of ARF1 at the cell membrane [126]. Mutations in *FLNA* lead to X-linked periventricular nodular heterotopia (PVNH1; MIM #300049), characterized by brain structural abnormalities and ID, at least in males, but with no known microcephaly (reviewed in [127]).

Mutations in the gene for phosphofurin acidic cluster sorting protein, PACS1, a *trans*-Golgi protein involved in the trafficking of FURIN, lead to Schuurs-Hoeijmakers syndrome, an autosomal dominant mental retardation (MRD17; MIM #615009), characterized by ID, dysmorphic features, and brain MRI defects in addition to skeletal defects [128].

Similarly, autosomal recessive mutations in *SCYL1*, which encodes a protein located at the interface between the GA and COPI-coated vesicles and likely involved in trafficking functions, lead to another form of autosomal recessive spinocerebellar ataxia (SCAR21; MIM #616719), characterized by cerebellar atrophy, peripheral neuropathy and mild ID [129].

Several mutations in the *BICD2* gene, which encodes the golgin BICAUDAL2 that interacts with the dynein-dynactin motor complex and RAB6A, have been shown to cause an autosomal dominant form of spinal muscular atrophy (SMALED2; MIM #615290) [130-132]. Similarly, mutations in *KIF1C*, a kinesin family motor protein that interacts with RAB6 to mediate GA tethering [133], lead to an autosomal recessive form of hereditary spastic paraplegia, spastic ataxia 2 (SPAX2; MIM #611302) [134-136].

Mutations in the *TANGO2* gene, which encodes a protein thought to be involved in loading cargo into vesicles at the ER but is also localized at the GA, lead to a complex syndrome characterized by metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration (MECRCN; MIM #616878), with multiple neurodevelopmental manifestations including seizures and ataxia [137,138].

Mutations in *GOSR2*, a GA SNARE complex member, lead to early-onset ataxia and progressive myoclonic epilepsy (EPM6; MIM #614018) in childhood and skeletal deformities by adolescence [139,140].

A *cis*-Golgi protein encoded by *RETREG1* or *FAM134B* has been found to be mutated in hereditary sensory and autonomic neuropathy type IIB (HSAN2B; MIM #613115),

characterized by childhood onset autonomic neuropathy, and heavily impaired sensory and sometimes motor function [141].

Among the GA-associated genes involved in sensorineural loss, *OSBPL2*, which encodes a fatty-acid receptor, oxysterol binding protein-like protein 2, is mutated in a nonsyndromic autosomal dominant form of deafness with childhood onset (DFNA67; MIM #616340) [142,143]. In Hermansky-Pudlak syndrome 1 (HPS1, MIM #203300), a syndrome usually characterized in humans by albinism and excessive bleeding, as in HPS2 (discussed in Section II), mutations in the AP3D1 adaptor complex subunit give rise to a phenotype hearing loss in addition to neurodevelopmental delay and generalized seizures (HSP10; MIM #617050) [144]. Several of the genes and syndromes described above also have an impact on vision (several AP and COG subunits, RAB3GAP2, and TBC1D20, to name a few).

Sometimes, mutations in GA genes that are not thought to be associated with neurological symptoms might in fact have unnoticed neurodevelopmental effects, as in the case of the Hermansky-Pudlak syndromes, as seen above. In other cases, disorders considered to be neurodegenerative might have a neurodevelopmental component in rare early onset forms, such as some spinocerebellar ataxias: type 2 (MIM #183090, *ATXN2*), type 5 and 14 (MIM #600224; MIM #615386, *SPTBN2*) and type 8 (MIM #610743, *SYNE1*) [145].

The GA also plays an essential role in the biosynthesis or modification of the cargo being transported. While these are generally considered to be "metabolic" disorders and are related more to the modification of trafficked molecules than to trafficking per se, mutations in many of these also have neurodevelopmental consequences (for a brief overview, see [72]). For instance, it is the site of synthesis of some glycolipids and sphingomyelin, a major component of myelin and essential for normal morphogenesis or plasticity of membrane-rich cell types such as neurons (during migration, rapid axonal growth or dendritic arborization etc.) or oligodendrocytes (for the generation of the myelin sheath), from lipid precursors synthesized in

the ER (glycerol phospholipids, cholesterol and ceramide). Mutations in genes involved in lipid biosynthesis and processing have also been associated with several neurodevelopmental defects. For example, a mutation in *ACER3*, encoding an ER and Golgi ceramidase involved in sphingolipid metabolism, has been identified in a family with progressive impairment and regression of neurodevelopment during the first year of life, leukodystrophy-like signs and peripheral neuropathy (PLDECO, MIM #617762) [146]. Another GA gene involved in lipid metabolism and that leads to neurodevelopmental deficits is that encoding DDHD domain containing 2 (DDHD2), a phospholipase with a major role in brain triglyceride metabolism [147], mutations in which result in hereditary spastic paraplegia type 54 (SPG54, MIM #615033) [148]. Mutations in the *PGAP2* and *PGAP3* genes (post-GPI attachment to proteins 2 and 3), which are essential for the glycolipid remodeling of GPI anchor proteins, have been associated with developmental delays and ID, in addition to microcephaly in several families (HPMRS3, MIM #614207 and HPMRS4, MIM #615716) [149-153], while *PGAP1* has also been linked to ID [154,155].

Among the cargo-modifying enzymes present in the GA are a very large complement of different glycosyltransferases and glycosidases, in addition to enzymes responsible for adding or removing phosphate, sulphate, lipid and other groups from proteins. To give a few examples, mutations in the acetylglucosaminyltransferase gene *MGAT2*, a member of the N-glycosylation pathway, lead to CDG type IIa (CDG2A, MIM #212066), characterized by seizures, developmental delays and ID in addition to other symptoms [156]. Another member of the N-glycosylation pathway is β 1,4 galactosyltransferase I, implicated in severe forms of CDG-IIc (CDG2D, MIM #607091) with neurological deficits, hydrocephalus, myopathy and defective blood clotting [157]. CDG type II is also caused by mutations in the mannosidase gene *MAN1B1*, which lead to a syndrome characterized by ID and truncal obesity, while *INPP5E* (inositol polyphosphate-5-phosphatase E) mutations have been implicated in the neurodevelopmental disorders Joubert (JBTS1, MIM #213300) and MORM syndromes

(MORMS, MIM #610156) [158,159], the latter of which also includes ID and truncal obesity. Several types of muscular dystrophy with neurological involvement are also caused by defects in GA glycosylation genes (e.g. FKR, LARGE, POMGnT1). Similarly, a variety of members of the solute carrier families (SLC), which transport various metabolites (sugars, acetylCoA, zinc...) are involved in CDGs and other neurodevelopmental disorders including spastic paraplegias, ID, epilepsy etc [2].

Another GA protein family is that of the copper-transporting P-type ATPases, ATP7A and B (reviewed in [160]), which are specifically trafficked by AP1S1, whose mutation causes MEDNIK syndrome (mentioned in Section I above). Under basal conditions, ATP7A and B, which are ion pumps, are located in the *trans*-Golgi network (TGN) and translocates copper across intracellular membranes into the secretory pathway for incorporation into copper-dependent enzymes. Their mutation, while having multisystemic consequences due to copper deposition in the liver and skin, for example, in addition to the brain, has been linked to Menkes disease (MNK, MIM #309400) or occipital horn syndrome (OHS, MIM #304150), or spinal muscular atrophy (SMAX3, MIM #300489) (ATP7A), all disorders with a childhood onset, or dystonia and neurodegeneration of either childhood or late onset (ATP7B).

The link between Golgipathies, GA function and neurodevelopment

What is the explanation for the exceptionally large spectrum of diseases and symptoms associated with defective GA proteins above, even when one limits the discussion to those with neurodevelopmental consequences?

The GA is not only involved in but lies at the crossroads of a number of distinct and crucial cellular processes, some of which have only recently begun to be elucidated. In addition, individual GA proteins themselves often participate in more than one function or

pathway, depending on the cellular context, developmental stage and the pathophysiological state, and some proteins, such as the small RAB GTPases, belong to extended families with a whole gamut of functions, both within and outside the GA. However, much is still unknown regarding the precise functions and the molecular partners of the great majority of GA proteins, and existing information often comes from lower species or organs outside the nervous system. Despite these overlaps and restrictions, obtaining even an incomplete understanding of some of these functions and proteins may provide insights into the complex repercussions of their mutation or deregulation, including the various neurodevelopmental processes impacted. **Figure 1** illustrates the relationship between some of the principal GA functions and the different stages of neurodevelopment in which they are implicated, taking the central nervous system as an example. Understanding these functions and how they evolve over the lifespan of the cell and the organism would also help elucidate the reason why mutations in some families of GA proteins appear to cause a spectrum of deficits rather than discrete phenotypic entities (e.g. both congenital microcephalies and POM in the case of defective TRAPP, AP or SLC complex subunits).

Maintenance of GA structure, integrity and position:

A distinctive characteristic of the GA in the cells of mammals and other vertebrates is its structure – it is made up of stacks of flattened cisternae, as in protists, plants and invertebrates, but these stacks are linked to each other to form a "ribbon" [161,162]. Cisternal stacking is necessary for normal trafficking, while the ribbon structure is thought to play a role in higher order functions such as mitosis and apoptosis, cell polarity/migration and stress responses (reviewed in [163,164]). A number of GA proteins are involved in regulating this typical structure and the integrity of the GA. Prominent among these are various members of the coiled-coil golgin family of proteins (e.g. GM130, GINTIN, P115, GOLGIN-45, GMAP210, GIRDIN etc.), many of which interact with coiled-coil GRASP proteins and small

GTPases or GTP-binding proteins of the RAB, ARF and ARL families to control cisternal structure and stacking in the GA. (reviewed in [163-165]). Many of the GA-associated GTPases are in turn regulated by families of regulatory proteins, such as the GEFs and GAPs, which act at various points and target effector molecules in the trafficking pathway. Among the GA-associated members of these large families of proteins, some are specifically expressed in neural tissue, for example RAB6B [166] and to some extent RAB6C [167]. Several golgins (e.g. Bicaudal D and GMAP210) and RAB GTPases (for instance, the multifunctional RAB6) are involved in interactions between the GA and the microtubule cytoskeleton, including molecular motors such as DYNEIN, and help in the organization of the GA ribbon by recruiting GA stacks to the microtubule organizing center (MTOC). Some, such as GM130, through their interactions with other polarity-determining kinases as well as their role in microtubule nucleation and organization ([168-171]), dictate the polarity of the GA and thus of the cell or neuron as a whole [172], thus controlling its correct differentiation and function. The fragmentation of the GA ribbon through the phosphorylation of the GRASPs and other molecules might also allow GA repositioning and thus migration, growth or differentiation [173] (fragmentation is also essential for the progression of the cell cycle, discussed below). In addition to structural changes, GM130 and GRASP65 also form part of signaling cascades that regulate cell migration [170].

Secretory and membrane trafficking:

GA structure and integrity and many of the large array of molecules that control them are also essential for the various steps involved in vesicular transport – coat components and adaptors that control vesicle targeting and recognition, the coiled-coil golgins necessary for their capture and the SNAREs and COGs that help in tethering and fusion, RAB and other small GTPases that mediate the choreographed attachment and detachment of molecules at each step, adaptors, activators and inhibitors for each of the above etc. Interfering with these

proteins or their interactions results in disrupted GA structure/organization and abnormal protein and lipid transport (see for example the effects of disrupting various RABs on GA structure, reviewed in [174]), important for both neuronal and oligodendrocyte function, including the rapid membrane expansion needed for the establishment of neuronal outgrowth and connectivity and myelination. Mutations in these genes are involved in a number of Golgipathies with diverse symptoms, including the large majority of the POM syndromes with white matter defects that we have listed above (Dyggve-Melchior-Clausen syndrome, Warburg-Micro and Martsolf Syndromes, Cohen Syndrome Progressive Cerebello-Cerebral Atrophy Type 2 and other Pontocerebellar Hypoplasias, microcephalies related to mutations in the TRAPP complex and COG-related CDGs, to name a few) as well as a range of spinal muscular atrophies and paraplegias. Other functional consequences could be the disruption of neuronal migration to the appropriate target layers or regions, as a consequence both of membrane trafficking deficits and the disruption of the MTOC function of the GA and thus of cellular polarity [4]. Certain syndromes characterized by epilepsy or seizures could thus be a result of either the aberrant connectivity caused by such migration defects, or the defective transport of neurotransmitters or their receptors/inhibitors to the synapse. Additionally, the occurrence of central hypogonadism, dwarfism, obesity etc. of unknown etiology in certain POM Golgipathies could conceivably be due to deficits in neuroendocrine secretory activity controlling bodily hormonal homeostasis.

Cell cycle regulation:

Closely related to the structure and position of the GA is its role in the cell cycle. The typical ribbon structure of the GA in mammalian cells is usually localized close to the centrosome, a position regulated among others by a number of GA-associated proteins, including those involved in its structure and trafficking function (see for review [175]). During mitosis, the GA loses its pericentriolar position, as it does its ability to function as an

1 independent MTOC, and undergoes fragmentation to yield small tubular-reticular structures
2 and dispersed vesicles. While GA fragmentation could be considered a logical prerequisite for
3 the partitioning of the GA into the daughter cells, it appears that GA fragmentation is in fact a
4 prerequisite for mitosis itself, and blocking GA fragmentation, for example by blocking
5 GRASP phosphorylation, acts as a "Golgi checkpoint" for the progression of mitosis [176-178].
6 Failure of the GA to fragment results in the failure of Aurora-A recruitment at the centrosome,
7 essential for mitosis [179]. Several other GA proteins (for example GM130 and golgin-84) as
8 well as non-GA proteins are also activated during fragmentation. In addition, a number of RAB
9 GTPases including several GA-associated RABs, as well as the small G-protein ARF1 along
10 with its activators and effectors, play essential roles at various steps of mitosis. Surprisingly,
11 several GA proteins acquire new locations and functions during mitosis (reviewed in [177]).
12 Some GA proteins, such as GM130, whose role in this regard has been described above, may
13 also play very specific roles in neurogenesis and neural progenitor division, by influencing cell
14 polarity (reviewed in [180]) or the symmetry of mitosis, which plays a crucial role in the
15 generation of different types of neuronal progenitors while still maintaining the pool of stem
16 cells. For example, the asymmetric division of neural progenitor cells requires the interaction of
17 the golgin GCP60 (also known as ACBD3 or PAP7) and Numb [181]. While the
18 pathophysiological mechanisms underlying the syndromes characterized by macrocephaly
19 mentioned above are not clear, most of the mutations detected result in a loss of function, and it
20 is conceivable that uncontrolled proliferation or the dysregulation of the timing of symmetric
21 versus asymmetric divisions during neurogenesis, could lead to the overproduction of certain
22 neurons. In another instance of the overlap between the trafficking function of the GA and its
23 role in neurogenesis, the *trans*-Golgi BIG2 protein encoded by *ARFGEF2*, essential for protein
24 trafficking, is also involved in normal neural progenitor cell proliferation, migration and axonal
25 growth in the developing mammalian cortex through its interaction with RAB11, another *trans*-
26 Golgi protein. The early microcephaly and aberrant corticogenesis noted in ARPHN, caused by

ARFGEF2 mutations [59-62], could for example be due to defective neurogenesis and migration rather than defects in neuronal maturation or myelination.

It should not be forgotten that mutations in GA proteins whose function is essential early in neurodevelopment, for example during neurogenesis, might simply be embryonic lethal and thus pass unremarked.

Autophagy and apoptosis:

At the other end of the spectrum from cell proliferation and membrane expansion, the GA is also involved in normal or pathological cell death or the destruction of cellular contents. Both apoptosis and autophagy are normally occurring processes by which unwanted cells or cellular components are eliminated while limiting tissue damage (i.e. leakage of cellular contents). They occur during neurodevelopment, when the large excess of new neurons or membranes produced is culled during the maturation of the CNS. In addition, they are also brought into play for the removal of damaged cells during conditions of stress or disease. In fact, the GA is increasingly thought to play a role in sensing stress and reestablishing cellular homeostasis; prolonged "Golgi stress", like ER stress, while not due to an intrinsic GA defect, nevertheless leads to impaired or abnormal GA function, contributing to pathogenesis and cell death, including by novel mechanisms other than apoptosis [182].

In autophagy, or more specifically, macroautophagy, cellular contents to be degraded are enveloped in a "phagophore" or "isolation membrane" and delivered to acidic lysosomes for destruction. There is evidence that the phagophore might bud directly from GA membranes, or alternatively, from the ER or ER-Golgi Intermediate Compartment [183,184]. The GA might additionally be directly involved in the degradation of undesirable cellular contents [185]. Several GA-associated RAB GTPases and their partners, normally involved in various stages of trafficking, also play key roles in the formation of the autophagosome [186-190], as do SNAREs, which are involved in autophagosome fusion (reviewed in [191]). Among other GA

proteins, BECLIN1, a *trans*-Golgi protein involved in endosome-to-GA recycling, also plays a crucial early role in autophagosome formation (reviewed in [192]), by interacting with UVRAG, which normally mediates GA-to-ER retrograde transport by tethering COPI-coated vesicles but is displaced during autophagy [193]. Similarly, the *trans*-Golgi membrane-bound protein ATG9 is found in vesicles that contribute to autophagosome formation [188], and the regulation of its trafficking plays a crucial role in the induction of autophagy pathways [194,195]. Several coat adaptor proteins of the AP1, 2 and 4 classes are known to interact with ATG9, and are also necessary for autophagosome formation [196,197].

Apoptosis, resulting from mitochondrial membrane permeabilization in response to internal or external signals and leading cell death by strictly regulated molecular and cellular mechanisms, is mediated by members of the caspase and BCL-2 families of proteins. Much of the evidence for the involvement of GA proteins in apoptosis comes from neurodegenerative disorders such as Alzheimer, Parkinson and Huntington Diseases, where the GA undergoes stress due to an accumulation of aberrant and misfolded proteins or peptides, also causing it to fragment (reviewed in [198-200]). However, some of the early machinery for apoptosis localize to the GA, and is involved in cleaving various GA proteins that also play a role in neurodevelopment (for example GRASP65, GM130 or GIANTIN). Their cleavage triggers the mitosis-like disassembly of the GA and subsequent apoptosis (reviewed in [201]). Some GA proteins also have a larger signal transduction role – GMAP210 and golgin-160 as well as cleaved p115 fragments are translocated to the nucleus during apoptosis, triggering further apoptotic changes [202,203]. It is certainly possible that mutations that interfere with the cleavage of such GA proteins or that lead to the production of truncated proteins would either curtail or augment apoptosis, with consequences for neurodevelopment ranging from insufficient neurogenesis to excess neurons that are not culled and that lead to macrocephaly, aberrant connectivity and related disorders.

Biosynthesis and processing of lipids and proteins:

As mentioned previously, the GA is also intimately involved in the post-translational modification of proteins and the biosynthesis of some lipids. In terms of the physiological effects of mutations in these proteins versus mutations in proteins involved in trafficking per se, there might be a convergence, since the functional consequences of the lack of delivery of a modified protein to its target intracellular compartment and the lack of its modification in the first place are likely to be similar in at least some respects. In addition, the highly specialized nature of the nervous system implies a corresponding adaptation of GA trafficking function in the component cells (for example, the occurrence of Golgi outposts in dendrites), and correspondingly, defects in GA enzyme function often lead to neurological consequences (also reviewed in [2,4]). A prime example of this convergence is provided by the CDGs, which could be related to structural/mechanical deficits (e.g. due to the mutation of COG subunits necessary for vesicle tethering) or due to enzymatic deficits (due to the failure of glycosylation).

Conclusion

While the large number of neurodevelopmental Golgipathies described in this review contain some surprises, it appears as if the majority were, and are, simply hiding in plain sight. The GA is involved in a very large range of functions spanning every stage of a cell's lifespan; an even larger number of overlapping GA-associated proteins and pathways carry out or regulate these functions. It is therefore to be expected that as our knowledge of these proteins and pathways grows, and as modern sequencing methods provide a molecular diagnosis for more obscure syndromes, the range of phenotypes that we know to be caused by defective GA proteins and their partners will expand. This is especially true when one considers the essential roles played by the GA in the formation, growth and maturation of the brain and nervous system. In fact, the spectrum of syndromes in which mutations in GA-associated proteins are

implicated, and the overlap in the cellular roles played by these proteins, evoke the intriguing idea that the GA might modify its role in keeping with the needs of the cell or the organism during its lifespan. For instance, the same proteins that are actively involved in cell cycle initiation or regulation during neurogenesis, when abundant proliferation is required, might be repurposed to lend a hand in neuronal migration, apoptosis or maturation, meet secretory trafficking needs during synaptogenesis and myelination as well as normal cellular function for the major part of the lifespan of the cell, and finally play a role in repair and damage control during aging (see also [204]). From this perspective, this vast array of neurodevelopmental Golgipathies appears not as isolated syndromes that differ from each other, but as points that fall along a few key functional continua, with flexible phenotypes that primarily reflect the developmental stage at which function is interrupted or altered. Such an organelle-centric approach might eventually make it easier to understand the pathophysiology of these disorders.

Acknowledgements

We are grateful to Cécile Martel for invaluable support. This work was supported by the Institut National pour la Santé et la Recherche Médicale (INSERM), the Centre National de la Recherche Scientifique (CNRS), the Université Paris 7, DHU PROTECT, and European and national grants from the French National Research Agency (ANR-13-RARE-0007-01 to AV, SP and VEG (ERA-NET E-Rare 2013, EuroMicro project), ANR-15-NEUR-0003-01 to PG (ERA-NET Neuron, MicroKin project), and ANR-16-CE16-0024-01 to VEG (PRC GENERIQUE 2016, MicroGol project).

1 References

- 2 1 Golgi C: On the structure of nerve cells. 1898. *Journal of microscopy* 1989;155:3-7.
- 3 2 Zappa F, Failli M, De Matteis MA: The Golgi complex in disease and therapy. *Curr Opin Cell Biol*
- 4 2018;50:102-116.
- 5 3 Hanus C, Ehlers MD: Specialization of biosynthetic membrane trafficking for neuronal form and
- 6 function. *Curr Opin Neurobiol* 2016;39:8-16.
- 7 4 Passemard S, Perez F, Colin-Lemesre E, Rasika S, Gressens P, El Ghouzzi V: Golgi trafficking
- 8 defects in postnatal microcephaly: The evidence for "Golgipathies". *Prog Neurobiol* 2017;153:46-
- 9 63.
- 10 5 Dupuis N, Fafouri A, Bayot A, Kumar M, Lecharpentier T, Ball G, Edwards D, Bernard V,
- 11 Dournaud P, Drunat S, Vermelle-Andrzejewski M, Vilain C, Abramowicz M, Desir J, Bonaventure
- 12 J, Gareil N, Boncompain G, Csaba Z, Perez F, Passemard S, Gressens P, El Ghouzzi V: Dymeclin
- 13 deficiency causes postnatal microcephaly, hypomyelination and reticulum-to-Golgi trafficking
- 14 defects in mice and humans. *Hum Mol Genet* 2015;24:2771-2783.
- 15 6 Dimitrov A, Paupe V, Gueudry C, Sibarita JB, Raposo G, Vielemeyer O, Gilbert T, Csaba Z, Attie-
- 16 Bitach T, Cormier-Daire V, Gressens P, Rustin P, Perez F, El Ghouzzi V: The gene responsible for
- 17 Dyggve-Melchior-Clausen syndrome encodes a novel peripheral membrane protein dynamically
- 18 associated with the Golgi apparatus. *Hum Mol Genet* 2009;18:440-453.
- 19 7 Osipovich AB, Jennings JL, Lin Q, Link AJ, Ruley HE: Dyggve-Melchior-Clausen syndrome:
- 20 chondrodysplasia resulting from defects in intracellular vesicle traffic. *Proc Natl Acad Sci U S A*
- 21 2008;105:16171-16176.
- 22 8 Paupe V, Gilbert T, Le Merrer M, Munnich A, Cormier-Daire V, El Ghouzzi V: Recent advances
- 23 in Dyggve-Melchior-Clausen syndrome. *Mol Genet Metab* 2004;83:51-59.
- 24 9 Goud B, Gleeson PA: TGN golgins, Rabs and cytoskeleton: regulating the Golgi trafficking
- 25 highways. *Trends in cell biology* 2010;20:329-336.
- 26 10 Koreishi M, Gniadek TJ, Yu S, Masuda J, Honjo Y, Satoh A: The golgin tether giantin regulates
- 27 the secretory pathway by controlling stack organization within Golgi apparatus. *PLoS One*
- 28 2013;8:e59821.
- 29 11 Rosing M, Ossendorf E, Rak A, Barnekow A: Giantin interacts with both the small GTPase Rab6
- 30 and Rab1. *Experimental cell research* 2007;313:2318-2325.
- 31 12 Cohn DH, Ehtesham N, Krakow D, Unger S, Shanske A, Reinker K, Powell BR, Rimoin DL:
- 32 Mental retardation and abnormal skeletal development (Dyggve-Melchior-Clausen dysplasia) due
- 33 to mutations in a novel, evolutionarily conserved gene. *Am J Hum Genet* 2003;72:419-428.
- 34 13 Alshammari MJ, Al-Otaibi L, Alkuraya FS: Mutation in RAB33B, which encodes a regulator of
- 35 retrograde Golgi transport, defines a second Dyggve-Melchior-Clausen locus. *J Med Genet*
- 36 2012;49:455-461.
- 37 14 Dupuis N, Lebon S, Kumar M, Drunat S, Graul-Neumann LM, Gressens P, El Ghouzzi V: A Novel
- 38 RAB33B Mutation in Smith-McCort Dysplasia. *Hum Mutat* 2013;34:283-286.
- 39 15 Warburg M, Sjo O, Fledelius HC, Pedersen SA: Autosomal recessive microcephaly, microcornea,
- 40 congenital cataract, mental retardation, optic atrophy, and hypogenitalism. *Micro syndrome. Am J*
- 41 *Dis Child* 1993;147:1309-1312.
- 42 16 Bem D, Yoshimura S, Nunes-Bastos R, Bond FC, Kurian MA, Rahman F, Handley MT, Hadzhiev
- 43 Y, Masood I, Straatman-Iwanowska AA, Cullinane AR, McNeill A, Pasha SS, Kirby GA, Foster K,
- 44 Ahmed Z, Morton JE, Williams D, Graham JM, Dobyns WB, Burglen L, Ainsworth JR, Gissen P,
- 45 Muller F, Maher ER, Barr FA, Aligianis IA: Loss-of-function mutations in RAB18 cause Warburg
- 46 micro syndrome. *Am J Hum Genet* 2011;88:499-507.
- 47 17 Handley MT, Morris-Rosendahl DJ, Brown S, Macdonald F, Hardy C, Bem D, Carpanini SM,
- 48 Borck G, Martorell L, Izzi C, Faravelli F, Accorsi P, Pinelli L, Basel-Vanagaite L, Peretz G, Abdel-
- 49 Salam GM, Zaki MS, Jansen A, Mowat D, Glass I, Stewart H, Mancini G, Lederer D, Roscioli T,
- 50 Giuliano F, Plomp AS, Rolfs A, Graham JM, Seemanova E, Poo P, Garcia-Cazorla A, Ederly P,
- 51 Jackson IJ, Maher ER, Aligianis IA: Mutation spectrum in RAB3GAP1, RAB3GAP2, and RAB18
- 52 and genotype-phenotype correlations in warburg micro syndrome and Martsolf syndrome. *Hum*
- 53 *Mutat* 2013;34:686-696.
- 54 18 Liegel RP, Handley MT, Ronchetti A, Brown S, Langemeyer L, Linford A, Chang B, Morris-
- 55 Rosendahl DJ, Carpanini S, Posmyk R, Harthill V, Sheridan E, Abdel-Salam GM, Terhal PA,

- 1 Faravelli F, Accorsi P, Giordano L, Pinelli L, Hartmann B, Ebert AD, Barr FA, Aligianis IA,
2 Sidjanin DJ: Loss-of-function mutations in TBC1D20 cause cataracts and male infertility in blind
3 sterile mice and Warburg micro syndrome in humans. *Am J Hum Genet* 2013;93:1001-1014.
- 4 19 Aligianis IA, Johnson CA, Gissen P, Chen D, Hampshire D, Hoffmann K, Maina EN, Morgan NV,
5 Tee L, Morton J, Ainsworth JR, Horn D, Rosser E, Cole TR, Stolte-Dijkstra I, Fieggen K, Clayton-
6 Smith J, Megarbane A, Shield JP, Newbury-Ecob R, Dobyns WB, Graham JM, Jr., Kjaer KW,
7 Warburg M, Bond J, Trembath RC, Harris LW, Takai Y, Mundlos S, Tannahill D, Woods CG,
8 Maher ER: Mutations of the catalytic subunit of RAB3GAP cause Warburg Micro syndrome. *Nat*
9 *Genet* 2005;37:221-223.
- 10 20 Borck G, Wunram H, Steiert A, Volk AE, Korber F, Roters S, Herkenrath P, Wollnik B, Morris-
11 Rosendahl DJ, Kubisch C: A homozygous RAB3GAP2 mutation causes Warburg Micro syndrome.
12 *Hum Genet* 2011;129:45-50.
- 13 21 Dejgaard SY, Murshid A, Erman A, Kizilay O, Verbich D, Lodge R, Dejgaard K, Ly-Hartig TB,
14 Pepperkok R, Simpson JC, Presley JF: Rab18 and Rab43 have key roles in ER-Golgi trafficking. *J*
15 *Cell Sci* 2008;121:2768-2781.
- 16 22 Handley MT, Carpanini SM, Mali GR, Sidjanin DJ, Aligianis IA, Jackson IJ, FitzPatrick DR:
17 Warburg Micro syndrome is caused by RAB18 deficiency or dysregulation. *Open biology*
18 2015;5:150047.
- 19 23 Gerodopoulos A, Bastos RN, Yoshimura S, Anderson R, Carpanini S, Aligianis I, Handley MT,
20 Barr FA: Rab18 and a Rab18 GEF complex are required for normal ER structure. *The Journal of*
21 *cell biology* 2014;205:707-720.
- 22 24 Bora E, Cankaya T, Alpman A, Karaca E, Cogulu O, Tekgul H, Ozkinay F: A new case of Martsolf
23 syndrome. *Genetic counseling* 2007;18:71-75.
- 24 25 Hennekam RC, van de Meeberg AG, van Doorne JM, Dijkstra PF, Bijlsma JB: Martsolf syndrome
25 in a brother and sister: clinical features and pattern of inheritance. *European journal of pediatrics*
26 1988;147:539-543.
- 27 26 Deciphering Developmental Disorders S: Large-scale discovery of novel genetic causes of
28 developmental disorders. *Nature* 2015;519:223-228.
- 29 27 Mir A, Kaufman L, Noor A, Motazacker MM, Jamil T, Azam M, Kahrizi K, Rafiq MA, Weksberg
30 R, Nasr T, Naeem F, Tzschach A, Kuss AW, Ishak GE, Doherty D, Ropers HH, Barkovich AJ,
31 Najmabadi H, Ayub M, Vincent JB: Identification of mutations in TRAPPC9, which encodes the
32 NIK- and IKK-beta-binding protein, in nonsyndromic autosomal-recessive mental retardation. *Am*
33 *J Hum Genet* 2009;85:909-915.
- 34 28 Mochida GH, Mahajnah M, Hill AD, Basel-Vanagaite L, Gleason D, Hill RS, Bodell A, Crosier M,
35 Straussberg R, Walsh CA: A truncating mutation of TRAPPC9 is associated with autosomal-
36 recessive intellectual disability and postnatal microcephaly. *Am J Hum Genet* 2009;85:897-902.
- 37 29 Philippe O, Rio M, Carioux A, Plaza JM, Guigue P, Molinari F, Boddaert N, Bole-Feysot C,
38 Nitschke P, Smahi A, Munnich A, Colleaux L: Combination of linkage mapping and microarray-
39 expression analysis identifies NF-kappaB signaling defect as a cause of autosomal-recessive mental
40 retardation. *Am J Hum Genet* 2009;85:903-908.
- 41 30 Abou Jamra R, Wohlfart S, Zweier M, Uebe S, Priebe L, Ekici A, Giesebrecht S, Abboud A, Al
42 Khateeb MA, Fakher M, Hamdan S, Ismael A, Muhammad S, Nothen MM, Schumacher J, Reis A:
43 Homozygosity mapping in 64 Syrian consanguineous families with non-specific intellectual
44 disability reveals 11 novel loci and high heterogeneity. *Eur J Hum Genet* 2011;19:1161-1166.
- 45 31 Kakar N, Goebel I, Daud S, Nurnberg G, Agha N, Ahmad A, Nurnberg P, Kubisch C, Ahmad J,
46 Borck G: A homozygous splice site mutation in TRAPPC9 causes intellectual disability and
47 microcephaly. *Eur J Med Genet* 2012;55:727-731.
- 48 32 Marangi G, Leuzzi V, Manti F, Lattante S, Orteschi D, Pecile V, Neri G, Zollino M: TRAPPC9-
49 related autosomal recessive intellectual disability: report of a new mutation and clinical phenotype.
50 *Eur J Hum Genet* 2013;21:229-232.
- 51 33 Barrowman J, Bhandari D, Reinisch K, Ferro-Novick S: TRAPP complexes in membrane traffic:
52 convergence through a common Rab. *Nature reviews Molecular cell biology* 2010;11:759-763.
- 53 34 Barnekow A, Thyrock A, Kessler D: Chapter 5: rab proteins and their interaction partners.
54 *International review of cell and molecular biology* 2009;274:235-274.
- 55 35 Zong M, Satoh A, Yu MK, Siu KY, Ng WY, Chan HC, Tanner JA, Yu S: TRAPPC9 mediates the
56 interaction between p150 and COPII vesicles at the target membrane. *PLoS One* 2012;7:e29995.

- 36 Milev MP, Grout ME, Saint-Dic D, Cheng YH, Glass IA, Hale CJ, Hanna DS, Dorschner MO, Prematilake K, Shaag A, Elpeleg O, Sacher M, Doherty D, Edvardson S: Mutations in TRAPPC12 Manifest in Progressive Childhood Encephalopathy and Golgi Dysfunction. *Am J Hum Genet* 2017;101:291-299.
- 37 Marin-Valencia I, Novarino G, Johansen A, Rosti B, Issa MY, Musaev D, Bhat G, Scott E, Silhavy JL, Stanley V, Rosti RO, Gleeson JW, Imam FB, Zaki MS, Gleeson JG: A homozygous founder mutation in TRAPPC6B associates with a neurodevelopmental disorder characterised by microcephaly, epilepsy and autistic features. *J Med Genet* 2018;55:48-54.
- 38 Park SY, Yang JS, Schmider AB, Soberman RJ, Hsu VW: Coordinated regulation of bidirectional COPI transport at the Golgi by CDC42. *Nature* 2015;521:529-532.
- 39 Martinelli S, Krumbach OHF, Pantaleoni F, Coppola S, Amin E, Pannone L, Nouri K, Farina L, Dvorsky R, Lepri F, Buchholzer M, Konopatzki R, Walsh L, Payne K, Pierpont ME, Vergano SS, Langley KG, Larsen D, Farwell KD, Tang S, Mroske C, Gallotta I, Di Schiavi E, Della Monica M, Lugli L, Rossi C, Seri M, Cocchi G, Henderson L, Baskin B, Alders M, Mendoza-Londono R, Dupuis L, Nickerson DA, Chong JX, University of Washington Center for Mendelian G, Meeks N, Brown K, Causey T, Cho MT, Demuth S, Digilio MC, Gelb BD, Bamshad MJ, Zenker M, Ahmadian MR, Hennekam RC, Tartaglia M, Mirzaa GM: Functional Dysregulation of CDC42 Causes Diverse Developmental Phenotypes. *Am J Hum Genet* 2018
- 40 Shamseldin HE, Bennett AH, Alfadhel M, Gupta V, Alkuraya FS: GOLGA2, encoding a master regulator of golgi apparatus, is mutated in a patient with a neuromuscular disorder. *Hum Genet* 2016;135:245-251.
- 41 Nakamura N: Emerging new roles of GM130, a cis-Golgi matrix protein, in higher order cell functions. *Journal of pharmacological sciences* 2010;112:255-264.
- 42 Short B, Preisinger C, Korner R, Kopajtich R, Byron O, Barr FA: A GRASP55-rab2 effector complex linking Golgi structure to membrane traffic. *The Journal of cell biology* 2001;155:877-883.
- 43 Valsdottir R, Hashimoto H, Ashman K, Koda T, Storrie B, Nilsson T: Identification of rabaptin-5, rabex-5, and GM130 as putative effectors of rab33b, a regulator of retrograde traffic between the Golgi apparatus and ER. *FEBS Lett* 2001;508:201-209.
- 44 Alwadei AH, Benini R, Mahmoud A, Alasmari A, Kamsteeg EJ, Alfadhel M: Loss-of-function mutation in RUSC2 causes intellectual disability and secondary microcephaly. *Developmental medicine and child neurology* 2016;58:1317-1322.
- 45 Bayer M, Fischer J, Kremerskothen J, Ossendorf E, Matanis T, Konczal M, Weide T, Barnekow A: Identification and characterization of Iporin as a novel interaction partner for rab1. *BMC cell biology* 2005;6:15.
- 46 Wang H, Falk MJ, Wensel C, Traboulsi EI: Cohen Syndrome; in Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K (eds): *GeneReviews(R)*. Seattle (WA), 1993
- 47 Falk MJ, Feiler HS, Neilson DE, Maxwell K, Lee JV, Segall SK, Robin NH, Wilhelmsen KC, Traskelin AL, Kolehmainen J, Lehesjoki AE, Wiznitzer M, Warman ML: Cohen syndrome in the Ohio Amish. *Am J Med Genet A* 2004;128A:23-28.
- 48 Kivitie-Kallio S, Autti T, Salonen O, Norio R: MRI of the brain in the Cohen syndrome: a relatively large corpus callosum in patients with mental retardation and microcephaly. *Neuropediatrics* 1998;29:298-301.
- 49 Seifert W, Kuhnisch J, Maritzen T, Horn D, Haucke V, Hennies HC: Cohen syndrome-associated protein, COH1, is a novel, giant Golgi matrix protein required for Golgi integrity. *J Biol Chem* 2011;286:37665-37675.
- 50 Seifert W, Kuhnisch J, Maritzen T, Lommatzsch S, Hennies HC, Bachmann S, Horn D, Haucke V: Cohen syndrome-associated protein COH1 physically and functionally interacts with the small GTPase RAB6 at the Golgi complex and directs neurite outgrowth. *J Biol Chem* 2015;290:3349-3358.
- 51 Ben-Zeev B, Hoffman C, Lev D, Waternberg N, Malinger G, Brand N, Lerman-Sagie T: Progressive cerebellocerebral atrophy: a new syndrome with microcephaly, mental retardation, and spastic quadriplegia. *J Med Genet* 2003;40:e96.
- 52 Feinstein M, Flusser H, Lerman-Sagie T, Ben-Zeev B, Lev D, Agamy O, Cohen I, Kadir R, Sivan S, Leshinsky-Silver E, Markus B, Birk OS: VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2). *J Med Genet* 2014;51:303-308.

- 53 Bonifacino JS, Hierro A: Transport according to GARP: receiving retrograde cargo at the trans-Golgi network. *Trends in cell biology* 2011;21:159-167.
- 54 Schindler C, Chen Y, Pu J, Guo X, Bonifacino JS: EARP is a multisubunit tethering complex involved in endocytic recycling. *Nat Cell Biol* 2015;17:639-650.
- 55 Liewen H, Meinhold-Heerlein I, Oliveira V, Schwarzenbacher R, Luo G, Wadle A, Jung M, Pfreundschuh M, Stenner-Liewen F: Characterization of the human GARP (Golgi associated retrograde protein) complex. *Experimental cell research* 2005;306:24-34.
- 56 Ivanova EL, Mau-Them FT, Riazuddin S, Kahrizi K, Laugel V, Schaefer E, de Saint Martin A, Runge K, Iqbal Z, Spitz MA, Laura M, Drouot N, Gerard B, Deleuze JF, de Brouwer APM, Razzaq A, Dollfus H, Assir MZ, Nitchke P, Hinckelmann MV, Ropers H, Riazuddin S, Najmabadi H, van Bokhoven H, Chelly J: Homozygous Truncating Variants in TBC1D23 Cause Pontocerebellar Hypoplasia and Alter Cortical Development. *Am J Hum Genet* 2017;101:428-440.
- 57 Marin-Valencia I, Gerondopoulos A, Zaki MS, Ben-Omran T, Almureikhi M, Demir E, Guemez-Gamboa A, Gregor A, Issa MY, Appelhof B, Roosing S, Musaev D, Rosti B, Wirth S, Stanley V, Baas F, Barr FA, Gleeson JG: Homozygous Mutations in TBC1D23 Lead to a Non-degenerative Form of Pontocerebellar Hypoplasia. *Am J Hum Genet* 2017;101:441-450.
- 58 Shin JJH, Gillingham AK, Begum F, Chadwick J, Munro S: TBC1D23 is a bridging factor for endosomal vesicle capture by golgins at the trans-Golgi. *Nat Cell Biol* 2017;19:1424-1432.
- 59 Banne E, Atawneh O, Henneke M, Brockmann K, Gartner J, Elpeleg O, Edvardson S: West syndrome, microcephaly, grey matter heterotopia and hypoplasia of corpus callosum due to a novel ARFGEF2 mutation. *J Med Genet* 2013;50:772-775.
- 60 de Wit MC, de Coo IF, Halley DJ, Lequin MH, Mancini GM: Movement disorder and neuronal migration disorder due to ARFGEF2 mutation. *Neurogenetics* 2009;10:333-336.
- 61 Tanyalcin I, Verhelst H, Halley DJ, Vanderhasselt T, Villard L, Goizet C, Lissens W, Mancini GM, Jansen AC: Elaborating the phenotypic spectrum associated with mutations in ARFGEF2: case study and literature review. *European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society* 2013;17:666-670.
- 62 Sheen VL, Ganesh VS, Topcu M, Sebire G, Bodell A, Hill RS, Grant PE, Shugart YY, Imitola J, Khoury SJ, Guerrini R, Walsh CA: Mutations in ARFGEF2 implicate vesicle trafficking in neural progenitor proliferation and migration in the human cerebral cortex. *Nat Genet* 2004;36:69-76.
- 63 Bui QT, Golinelli-Cohen MP, Jackson CL: Large Arf1 guanine nucleotide exchange factors: evolution, domain structure, and roles in membrane trafficking and human disease. *Molecular genetics and genomics : MGG* 2009;282:329-350.
- 64 Kawauchi T, Sekine K, Shikanai M, Chihama K, Tomita K, Kubo K, Nakajima K, Nabeshima Y, Hoshino M: Rab GTPases-dependent endocytic pathways regulate neuronal migration and maturation through N-cadherin trafficking. *Neuron* 2010;67:588-602.
- 65 Nieuwenhuis B, Eva R: ARF6 and Rab11 as intrinsic regulators of axon regeneration. *Small GTPases* 2018;1-10.
- 66 Guardia CM, De Pace R, Mattera R, Bonifacino JS: Neuronal functions of adaptor complexes involved in protein sorting. *Curr Opin Neurobiol* 2018;51:103-110.
- 67 Martinelli D, Travaglini L, Drouin CA, Ceballos-Picot I, Rizza T, Bertini E, Carrozzo R, Petrini S, de Lonlay P, El Hachem M, Hubert L, Montpetit A, Torre G, Dionisi-Vici C: MEDNIK syndrome: a novel defect of copper metabolism treatable by zinc acetate therapy. *Brain* 2013;136:872-881.
- 68 Montpetit A, Cote S, Brustein E, Drouin CA, Lapointe L, Boudreau M, Meloche C, Drouin R, Hudson TJ, Drapeau P, Cossette P: Disruption of AP1S1, causing a novel neurocutaneous syndrome, perturbs development of the skin and spinal cord. *PLoS Genet* 2008;4:e1000296.
- 69 Saba TG, Montpetit A, Verner A, Rioux P, Hudson TJ, Drouin R, Drouin CA: An atypical form of erythrokeratoderma variabilis maps to chromosome 7q22. *Hum Genet* 2005;116:167-171.
- 70 Cacciagli P, Desvignes JP, Girard N, Delepine M, Zelenika D, Lathrop M, Levy N, Ledbetter DH, Dobyns WB, Villard L: AP1S2 is mutated in X-linked Dandy-Walker malformation with intellectual disability, basal ganglia disease and seizures (Pettigrew syndrome). *Eur J Hum Genet* 2014;22:363-368.
- 71 Pettigrew AL, Jackson LG, Ledbetter DH: New X-linked mental retardation disorder with Dandy-Walker malformation, basal ganglia disease, and seizures. *Am J Med Genet* 1991;38:200-207.
- 72 Freeze HH, Ng BG: Golgi glycosylation and human inherited diseases. *Cold Spring Harbor perspectives in biology* 2011;3:a005371.

- 73 Climer LK, Dobretsov M, Lupashin V: Defects in the COG complex and COG-related trafficking regulators affect neuronal Golgi function. *Frontiers in neuroscience* 2015;9:405.
- 74 Shestakova A, Zolov S, Lupashin V: COG complex-mediated recycling of Golgi glycosyltransferases is essential for normal protein glycosylation. *Traffic* 2006;7:191-204.
- 75 Foulquier F, Ungar D, Reynders E, Zeevaert R, Mills P, Garcia-Silva MT, Briones P, Winchester B, Morelle W, Krieger M, Annaert W, Matthijs G: A new inborn error of glycosylation due to a Cog8 deficiency reveals a critical role for the Cog1-Cog8 interaction in COG complex formation. *Hum Mol Genet* 2007;16:717-730.
- 76 Foulquier F, Vasile E, Schollen E, Callewaert N, Raemaekers T, Quelhas D, Jaeken J, Mills P, Winchester B, Krieger M, Annaert W, Matthijs G: Conserved oligomeric Golgi complex subunit 1 deficiency reveals a previously uncharacterized congenital disorder of glycosylation type II. *Proc Natl Acad Sci U S A* 2006;103:3764-3769.
- 77 Kodera H, Ando N, Yuasa I, Wada Y, Tsurusaki Y, Nakashima M, Miyake N, Saitoh S, Matsumoto N, Saitsu H: Mutations in COG2 encoding a subunit of the conserved oligomeric golgi complex cause a congenital disorder of glycosylation. *Clinical genetics* 2015;87:455-460.
- 78 Morava E, Zeevaert R, Korsch E, Huijben K, Wopereis S, Matthijs G, Keymolen K, Lefeber DJ, De Meirleir L, Wevers RA: A common mutation in the COG7 gene with a consistent phenotype including microcephaly, adducted thumbs, growth retardation, VSD and episodes of hyperthermia. *Eur J Hum Genet* 2007;15:638-645.
- 79 Reynders E, Foulquier F, Leao Teles E, Quelhas D, Morelle W, Rabouille C, Annaert W, Matthijs G: Golgi function and dysfunction in the first COG4-deficient CDG type II patient. *Hum Mol Genet* 2009;18:3244-3256.
- 80 Rymen D, Keldermans L, Race V, Regal L, Deconinck N, Dionisi-Vici C, Fung CW, Sturiale L, Rosnoblet C, Foulquier F, Matthijs G, Jaeken J: COG5-CDG: expanding the clinical spectrum. *Orphanet journal of rare diseases* 2012;7:94.
- 81 Yang A, Cho SY, Jang JH, Kim J, Kim SZ, Lee BH, Yoo HW, Jin DK: Further delineation of COG8-CDG: A case with novel compound heterozygous mutations diagnosed by targeted exome sequencing. *Clinica chimica acta; international journal of clinical chemistry* 2017;471:191-195.
- 82 Huybrechts S, De Laet C, Bontems P, Rooze S, Souayah H, Sznajer Y, Sturiale L, Garozzo D, Matthijs G, Ferster A, Jaeken J, Goyens P: Deficiency of Subunit 6 of the Conserved Oligomeric Golgi Complex (COG6-CDG): Second Patient, Different Phenotype. *JIMD reports* 2012;4:103-108.
- 83 Rymen D, Winter J, Van Hasselt PM, Jaeken J, Kasapkara C, Gokcay G, Haijes H, Goyens P, Tokatli A, Thiel C, Bartsch O, Hecht J, Krawitz P, Prinsen HC, Mildenerberger E, Matthijs G, Kornak U: Key features and clinical variability of COG6-CDG. *Mol Genet Metab* 2015;116:163-170.
- 84 Edvardson S, Ashikov A, J alas C, Sturiale L, Shaag A, Fedick A, Treff NR, Garozzo D, Gerardy-Schahn R, Elpeleg O: Mutations in SLC35A3 cause autism spectrum disorder, epilepsy and arthrogryposis. *J Med Genet* 2013;50:733-739.
- 85 Frydman M, Etzioni A, Eidlitz-Markus T, Avidor I, Varsano I, Shechter Y, Orlin JB, Gershoni-Baruch R: Rambam-Hasharon syndrome of psychomotor retardation, short stature, defective neutrophil motility, and Bombay phenotype. *Am J Med Genet* 1992;44:297-302.
- 86 Dulary E, Potelle S, Legrand D, Foulquier F: TMEM165 deficiencies in Congenital Disorders of Glycosylation type II (CDG-II): Clues and evidences for roles of the protein in Golgi functions and ion homeostasis. *Tissue & cell* 2017;49:150-156.
- 87 Foulquier F, Amyere M, Jaeken J, Zeevaert R, Schollen E, Race V, Bammens R, Morelle W, Rosnoblet C, Legrand D, Demaegd D, Buist N, Cheillan D, Guffon N, Morsomme P, Annaert W, Freeze HH, Van Schaftingen E, Vikkula M, Matthijs G: TMEM165 deficiency causes a congenital disorder of glycosylation. *Am J Hum Genet* 2012;91:15-26.
- 88 Nicholas AK, Khurshid M, Desir J, Carvalho OP, Cox JJ, Thornton G, Kausar R, Ansar M, Ahmad W, Verloes A, Passemard S, Misson JP, Lindsay S, Gergely F, Dobyns WB, Roberts E, Abramowicz M, Woods CG: WDR62 is associated with the spindle pole and is mutated in human microcephaly. *Nat Genet* 2010;42:1010-1014.
- 89 Yu TW, Mochida GH, Tischfield DJ, Sgaier SK, Flores-Sarnat L, Sergi CM, Topcu M, McDonald MT, Barry BJ, Felie JM, Sunu C, Dobyns WB, Folkerth RD, Barkovich AJ, Walsh CA: Mutations in WDR62, encoding a centrosome-associated protein, cause microcephaly with simplified gyri and abnormal cortical architecture. *Nat Genet* 2010;42:1015-1020.

- 90 Bogershausen N, Shahrzad N, Chong JX, von Kleist-Retzow JC, Stanga D, Li Y, Bernier FP, Loucks CM, Wirth R, Puffenberger EG, Hegele RA, Schreml J, Lapointe G, Keupp K, Brett CL, Anderson R, Hahn A, Innes AM, Suchowersky O, Mets MB, Nurnberg G, McLeod DR, Thiele H, Waggoner D, Altmuller J, Boycott KM, Schoser B, Nurnberg P, Ober C, Heller R, Parboosingh JS, Wollnik B, Sacher M, Lamont RE: Recessive TRAPPC11 mutations cause a disease spectrum of limb girdle muscular dystrophy and myopathy with movement disorder and intellectual disability. *Am J Hum Genet* 2013;93:181-190.
- 91 Fee DB, Harmelink M, Monrad P, Pyzik E: Siblings With Mutations in TRAPPC11 Presenting With Limb-Girdle Muscular Dystrophy 2S. *Journal of clinical neuromuscular disease* 2017;19:27-30.
- 92 Izumi K, Brett M, Nishi E, Drunat S, Tan ES, Fujiki K, Lebon S, Cham B, Masuda K, Arakawa M, Jacquinet A, Yamazumi Y, Chen ST, Verloes A, Okada Y, Katou Y, Nakamura T, Akiyama T, Gressens P, Foo R, Passemard S, Tan EC, El Ghouzzi V, Shirahige K: ARCN1 Mutations Cause a Recognizable Craniofacial Syndrome Due to COPI-Mediated Transport Defects. *Am J Hum Genet* 2016;99:451-459.
- 93 DiStasio A, Driver A, Sund K, Donlin M, Muraleedharan RM, Pooya S, Kline-Fath B, Kaufman KM, Prows CA, Schorry E, Dasgupta B, Stottmann RW: Copb2 is essential for embryogenesis and hypomorphic mutations cause human microcephaly. *Hum Mol Genet* 2017;26:4836-4848.
- 94 Nahorski MS, Asai M, Wakeling E, Parker A, Asai N, Canham N, Holder SE, Chen YC, Dyer J, Brady AF, Takahashi M, Woods CG: CCDC88A mutations cause PEHO-like syndrome in humans and mouse. *Brain* 2016;139:1036-1044.
- 95 Kim JY, Duan X, Liu CY, Jang MH, Guo JU, Pow-anpongkul N, Kang E, Song H, Ming GL: DISC1 regulates new neuron development in the adult brain via modulation of AKT-mTOR signaling through KIAA1212. *Neuron* 2009;63:761-773.
- 96 Fink JK: Hereditary spastic paraplegia: clinical principles and genetic advances. *Seminars in neurology* 2014;34:293-305.
- 97 Abou Jamra R, Philippe O, Raas-Rothschild A, Eck SH, Graf E, Buchert R, Borck G, Ekici A, Brockschmidt FF, Nothen MM, Munnich A, Strom TM, Reis A, Colleaux L: Adaptor protein complex 4 deficiency causes severe autosomal-recessive intellectual disability, progressive spastic paraplegia, shy character, and short stature. *Am J Hum Genet* 2011;88:788-795.
- 98 De Pace R, Skirzewski M, Damme M, Mattera R, Mercurio J, Foster AM, Cuitino L, Jarnik M, Hoffmann V, Morris HD, Han TU, Mancini GMS, Buonanno A, Bonifacino JS: Altered distribution of ATG9A and accumulation of axonal aggregates in neurons from a mouse model of AP-4 deficiency syndrome. *PLoS Genet* 2018;14:e1007363.
- 99 Moreno-De-Luca A, Helmers SL, Mao H, Burns TG, Melton AM, Schmidt KR, Fernhoff PM, Ledbetter DH, Martin CL: Adaptor protein complex-4 (AP-4) deficiency causes a novel autosomal recessive cerebral palsy syndrome with microcephaly and intellectual disability. *J Med Genet* 2011;48:141-144.
- 100 Verkerk AJ, Schot R, Dumee B, Schellekens K, Swagemakers S, Bertoli-Avella AM, Lequin MH, Dudink J, Govaert P, van Zwol AL, Hirst J, Wessels MW, Catsman-Berrevoets C, Verheijen FW, de Graaff E, de Coo IF, Kros JM, Willemsen R, Willems PJ, van der Spek PJ, Mancini GM: Mutation in the AP4M1 gene provides a model for neuroaxonal injury in cerebral palsy. *Am J Hum Genet* 2009;85:40-52.
- 101 Kotzot D, Richter K, Gierth-Fiebig K: Oculocutaneous albinism, immunodeficiency, hematological disorders, and minor anomalies: a new autosomal recessive syndrome? *Am J Med Genet* 1994;50:224-227.
- 102 Christianson AL, Stevenson RE, van der Meyden CH, Pelser J, Theron FW, van Rensburg PL, Chandler M, Schwartz CE: X linked severe mental retardation, craniofacial dysmorphology, epilepsy, ophthalmoplegia, and cerebellar atrophy in a large South African kindred is localised to Xq24-q27. *J Med Genet* 1999;36:759-766.
- 103 Gilfillan GD, Selmer KK, Roxrud I, Smith R, Kyllerman M, Eiklid K, Kroken M, Mattingdal M, Egeland T, Stenmark H, Sjoholm H, Server A, Samuelsson L, Christianson A, Tarpey P, Whibley A, Stratton MR, Futreal PA, Teague J, Edkins S, Gecz J, Turner G, Raymond FL, Schwartz C, Stevenson RE, Undlien DE, Stromme P: SLC9A6 mutations cause X-linked mental retardation, microcephaly, epilepsy, and ataxia, a phenotype mimicking Angelman syndrome. *Am J Hum Genet* 2008;82:1003-1010.

- 104 Schroer RJ, Holden KR, Tarpey PS, Matheus MG, Griesemer DA, Friez MJ, Fan JZ, Simensen RJ, Stromme P, Stevenson RE, Stratton MR, Schwartz CE: Natural history of Christianson syndrome. *Am J Med Genet A* 2010;152A:2775-2783.
- 105 Anazi S, Maddirevula S, Fageih E, Alsedairy H, Alzahrani F, Shamseldin HE, Patel N, Hashem M, Ibrahim N, Abdulwahab F, Ewida N, Alsaif HS, Al Sharif H, Alamoudi W, Kentab A, Bashiri FA, Alnaser M, AlWadei AH, Alfadhel M, Eyaid W, Hashem A, Al Asmari A, Saleh MM, AlSaman A, Alhasan KA, Alsughayir M, Al Shammari M, Mahmoud A, Al-Hassnan ZN, Al-Husain M, Osama Khalil R, Abd El Meguid N, Masri A, Ali R, Ben-Omran T, El Fishway P, Hashish A, Ercan Sencicek A, State M, Alazami AM, Salih MA, Altassan N, Arold ST, Abouelhoda M, Wakil SM, Monies D, Shaheen R, Alkuraya FS: Clinical genomics expands the morbid genome of intellectual disability and offers a high diagnostic yield. *Molecular psychiatry* 2017;22:615-624.
- 106 Han C, Alkhater R, Froukh T, Minassian AG, Galati M, Liu RH, Fotouhi M, Sommerfeld J, Alfrook AJ, Marshall C, Walker S, Bauer P, Scherer SW, Riess O, Buchert R, Minassian BA, McPherson PS: Epileptic Encephalopathy Caused by Mutations in the Guanine Nucleotide Exchange Factor DENND5A. *Am J Hum Genet* 2016;99:1359-1367.
- 107 Yoshimura S, Gerondopoulos A, Linford A, Rigden DJ, Barr FA: Family-wide characterization of the DENN domain Rab GDP-GTP exchange factors. *The Journal of cell biology* 2010;191:367-381.
- 108 Giannandrea M, Bianchi V, Mignogna ML, Sirri A, Carrabino S, D'Elia E, Vecellio M, Russo S, Cogliati F, Larizza L, Ropers HH, Tzschach A, Kalscheuer V, Oehl-Jaschkowitz B, Skinner C, Schwartz CE, Gecz J, Van Esch H, Raynaud M, Chelly J, de Brouwer AP, Toniolo D, D'Adamo P: Mutations in the small GTPase gene RAB39B are responsible for X-linked mental retardation associated with autism, epilepsy, and macrocephaly. *Am J Hum Genet* 2010;86:185-195.
- 109 Woodbury-Smith M, Deneault E, Yuen RKC, Walker S, Zarrei M, Pellicchia G, Howe JL, Hoang N, Uddin M, Marshall CR, Chrysler C, Thompson A, Szatmari P, Scherer SW: Mutations in RAB39B in individuals with intellectual disability, autism spectrum disorder, and macrocephaly. *Molecular autism* 2017;8:59.
- 110 Laxova R, Brown ES, Hogan K, Hecox K, Opitz JM: An X-linked recessive basal ganglia disorder with mental retardation. *Am J Med Genet* 1985;21:681-689.
- 111 Wilson GR, Sim JC, McLean C, Giannandrea M, Galea CA, Riseley JR, Stephenson SE, Fitzpatrick E, Haas SA, Pope K, Hogan KJ, Gregg RG, Bromhead CJ, Wargowski DS, Lawrence CH, James PA, Churchyard A, Gao Y, Phelan DG, Gillies G, Salce N, Stanford L, Marsh AP, Mignogna ML, Hayflick SJ, Leventer RJ, Delatycki MB, Mellick GD, Kalscheuer VM, D'Adamo P, Bahlo M, Amor DJ, Lockhart PJ: Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with alpha-synuclein pathology. *Am J Hum Genet* 2014;95:729-735.
- 112 Rosa JL, Casaroli-Marano RP, Buckler AJ, Vilaro S, Barbacid M: p619, a giant protein related to the chromosome condensation regulator RCC1, stimulates guanine nucleotide exchange on ARF1 and Rab proteins. *EMBO J* 1996;15:4262-4273.
- 113 Aggarwal S, Bhowmik AD, Ramprasad VL, Murugan S, Dalal A: A splice site mutation in HERC1 leads to syndromic intellectual disability with macrocephaly and facial dysmorphism: Further delineation of the phenotypic spectrum. *Am J Med Genet A* 2016;170:1868-1873.
- 114 Nguyen LS, Schneider T, Rio M, Moutton S, Siquier-Pernet K, Verny F, Boddaert N, Desguerre I, Munich A, Rosa JL, Cormier-Daire V, Colleaux L: A nonsense variant in HERC1 is associated with intellectual disability, megalencephaly, thick corpus callosum and cerebellar atrophy. *Eur J Hum Genet* 2016;24:455-458.
- 115 Ortega-Recalde O, Beltran OI, Galvez JM, Palma-Montero A, Restrepo CM, Mateus HE, Laissue P: Biallelic HERC1 mutations in a syndromic form of overgrowth and intellectual disability. *Clinical genetics* 2015;88:e1-3.
- 116 Reijnders MRF, Ansor NM, Kousi M, Yue WW, Tan PL, Clarkson K, Clayton-Smith J, Corning K, Jones JR, Lam WWK, Mancini GMS, Marcelis C, Mohammed S, Pfundt R, Roifman M, Cohn R, Chitayat D, Deciphering Developmental Disorders S, Millard TH, Katsanis N, Brunner HG, Banka S: RAC1 Missense Mutations in Developmental Disorders with Diverse Phenotypes. *Am J Hum Genet* 2017;101:466-477.
- 117 Bristow JM, Sellers MH, Majumdar D, Anderson B, Hu L, Webb DJ: The Rho-family GEF Asef2 activates Rac to modulate adhesion and actin dynamics and thereby regulate cell migration. *J Cell Sci* 2009;122:4535-4546.

- 118 Evans JC, Robinson CM, Shi M, Webb DJ: The guanine nucleotide exchange factor (GEF) Asef2 promotes dendritic spine formation via Rac activation and spinophilin-dependent targeting. *J Biol Chem* 2015;290:10295-10308.
- 119 Harripaul R, Vasli N, Mikhailov A, Rafiq MA, Mittal K, Windpassinger C, Sheikh TI, Noor A, Mahmood H, Downey S, Johnson M, Vleuten K, Bell L, Ilyas M, Khan FS, Khan V, Moradi M, Ayaz M, Naeem F, Heidari A, Ahmed I, Ghadami S, Agha Z, Zeinali S, Qamar R, Mozhdehipanah H, John P, Mir A, Ansar M, French L, Ayub M, Vincent JB: Mapping autosomal recessive intellectual disability: combined microarray and exome sequencing identifies 26 novel candidate genes in 192 consanguineous families. *Molecular psychiatry* 2018;23:973-984.
- 120 Bi W, Glass IA, Muzny DM, Gibbs RA, Eng CM, Yang Y, Sun A: Whole exome sequencing identifies the first STRADA point mutation in a patient with polyhydramnios, megalencephaly, and symptomatic epilepsy syndrome (PMSE). *Am J Med Genet A* 2016;170:2181-2185.
- 121 Puffenberger EG, Strauss KA, Ramsey KE, Craig DW, Stephan DA, Robinson DL, Hendrickson CL, Gottlieb S, Ramsay DA, Siu VM, Heuer GG, Crino PB, Morton DH: Polyhydramnios, megalencephaly and symptomatic epilepsy caused by a homozygous 7-kilobase deletion in LYK5. *Brain* 2007;130:1929-1941.
- 122 Rao S, Kirschen GW, Szczurkowska J, Di Antonio A, Wang J, Ge S, Shelly M: Repositioning of Somatic Golgi Apparatus Is Essential for the Dendritic Establishment of Adult-Born Hippocampal Neurons. *J Neurosci* 2018;38:631-647.
- 123 Bienvenu T, des Portes V, Saint Martin A, McDonell N, Billuart P, Carrie A, Vinet MC, Couvert P, Toniolo D, Ropers HH, Moraine C, van Bokhoven H, Fryns JP, Kahn A, Beldjord C, Chelly J: Non-specific X-linked semidominant mental retardation by mutations in a Rab GDP-dissociation inhibitor. *Hum Mol Genet* 1998;7:1311-1315.
- 124 D'Adamo P, Menegon A, Lo Nigro C, Grasso M, Gulisano M, Tamanini F, Bienvenu T, Gedeon AK, Oostra B, Wu SK, Tandon A, Valtorta F, Balch WE, Chelly J, Toniolo D: Mutations in GDI1 are responsible for X-linked non-specific mental retardation. *Nat Genet* 1998;19:134-139.
- 125 More L, Kunnecke B, Yekhelef L, Bruns A, Marte A, Fedele E, Bianchi V, Taverna S, Gatti S, D'Adamo P: Altered fronto-striatal functions in the Gdi1-null mouse model of X-linked Intellectual Disability. *Neuroscience* 2017;344:346-359.
- 126 Zhang J, Neal J, Lian G, Hu J, Lu J, Sheen V: Filamin A regulates neuronal migration through brefeldin A-inhibited guanine exchange factor 2-dependent Arf1 activation. *J Neurosci* 2013;33:15735-15746.
- 127 Chen MH, Walsh CA: FLNA-Related Periventricular Nodular Heterotopia; in Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A (eds): *GeneReviews*((R)). Seattle (WA), 1993
- 128 Schuurs-Hoeijmakers JH, Oh EC, Vissers LE, Swinkels ME, Gilissen C, Willemsen MA, Holvoet M, Steehouwer M, Veltman JA, de Vries BB, van Bokhoven H, de Brouwer AP, Katsanis N, Devriendt K, Brunner HG: Recurrent de novo mutations in PACS1 cause defective cranial-neural-crest migration and define a recognizable intellectual-disability syndrome. *Am J Hum Genet* 2012;91:1122-1127.
- 129 Schmidt WM, Rutledge SL, Schule R, Mayerhofer B, Zuchner S, Boltshauser E, Bittner RE: Disruptive SCYL1 Mutations Underlie a Syndrome Characterized by Recurrent Episodes of Liver Failure, Peripheral Neuropathy, Cerebellar Atrophy, and Ataxia. *Am J Hum Genet* 2015;97:855-861.
- 130 Martinez-Carrera LA, Wirth B: Dominant spinal muscular atrophy is caused by mutations in BICD2, an important golgin protein. *Frontiers in neuroscience* 2015;9:401.
- 131 Oates EC, Rossor AM, Hafezparast M, Gonzalez M, Speziani F, MacArthur DG, Lek M, Cottenie E, Scoto M, Foley AR, Hurler M, Houlden H, Greensmith L, Auer-Grumbach M, Pieber TR, Strom TM, Schule R, Herrmann DN, Sowden JE, Acsadi G, Menezes MP, Clarke NF, Zuchner S, Uk10K, Muntoni F, North KN, Reilly MM: Mutations in BICD2 cause dominant congenital spinal muscular atrophy and hereditary spastic paraplegia. *Am J Hum Genet* 2013;92:965-973.
- 132 Peeters K, Litvinenko I, Asselbergh B, Almeida-Souza L, Chamova T, Geuens T, Ydens E, Zimon M, Irobi J, De Vriendt E, De Winter V, Ooms T, Timmerman V, Tournay I, Jordanova A: Molecular defects in the motor adaptor BICD2 cause proximal spinal muscular atrophy with autosomal-dominant inheritance. *Am J Hum Genet* 2013;92:955-964.
- 133 Lee PL, Ohlson MB, Pfeffer SR: Rab6 regulation of the kinesin family KIF1C motor domain contributes to Golgi tethering. *eLife* 2015;4

- 134 Bouslam N, Bouhouche A, Benomar A, Hanein S, Klebe S, Azzedine H, Di Giandomenico S, Boland-Auge A, Santorelli FM, Durr A, Brice A, Yahyaoui M, Stevanin G: A novel locus for autosomal recessive spastic ataxia on chromosome 17p. *Hum Genet* 2007;121:413-420.
- 135 Caballero Oteyza A, Battaloglu E, Ocek L, Lindig T, Reichbauer J, Rebelo AP, Gonzalez MA, Zorlu Y, Ozes B, Timmann D, Bender B, Woehlke G, Zuchner S, Schols L, Schule R: Motor protein mutations cause a new form of hereditary spastic paraplegia. *Neurology* 2014;82:2007-2016.
- 136 Dor T, Cinnamon Y, Raymond L, Shaag A, Bouslam N, Bouhouche A, Gaussen M, Meyer V, Durr A, Brice A, Benomar A, Stevanin G, Schuelke M, Edvardson S: KIF1C mutations in two families with hereditary spastic paraparesis and cerebellar dysfunction. *J Med Genet* 2014;51:137-142.
- 137 Kremer LS, Distelmaier F, Alhaddad B, Hempel M, Iuso A, Kupper C, Muhlhause C, Kovacs-Nagy R, Satanovskij R, Graf E, Berutti R, Eckstein G, Durbin R, Sauer S, Hoffmann GF, Strom TM, Santer R, Meitinger T, Klopstock T, Prokisch H, Haack TB: Bi-allelic Truncating Mutations in TANGO2 Cause Infancy-Onset Recurrent Metabolic Crises with Encephalocardiomyopathy. *Am J Hum Genet* 2016;98:358-362.
- 138 Lalani SR, Liu P, Rosenfeld JA, Watkin LB, Chiang T, Leduc MS, Zhu W, Ding Y, Pan S, Vetrini F, Miyake CY, Shinawi M, Gambin T, Eldomery MK, Akdemir ZH, Emrick L, Wilnai Y, Schelley S, Koenig MK, Memon N, Farach LS, Coe BP, Azamian M, Hernandez P, Zapata G, Jhangiani SN, Muzny DM, Lotze T, Clark G, Wilfong A, Northrup H, Adesina A, Bacino CA, Scaglia F, Bonnen PE, Crosson J, Duis J, Maegawa GH, Coman D, Inwood A, McGill J, Boerwinkle E, Graham B, Beaudet A, Eng CM, Hanchard NA, Xia F, Orange JS, Gibbs RA, Lupski JR, Yang Y: Recurrent Muscle Weakness with Rhabdomyolysis, Metabolic Crises, and Cardiac Arrhythmia Due to Bi-allelic TANGO2 Mutations. *Am J Hum Genet* 2016;98:347-357.
- 139 Corbett MA, Schwake M, Bahlo M, Dibbens LM, Lin M, Gandolfo LC, Vears DF, O'Sullivan JD, Robertson T, Bayly MA, Gardner AE, Vlaar AM, Korenke GC, Bloem BR, de Coe IF, Verhagen JM, Lehesjoki AE, Gecz J, Berkovic SF: A mutation in the Golgi Qb-SNARE gene GOSR2 causes progressive myoclonus epilepsy with early ataxia. *Am J Hum Genet* 2011;88:657-663.
- 140 van Egmond ME, Verschuuren-Bemelmans CC, Nibbeling EA, Elting JW, Sival DA, Brouwer OF, de Vries JJ, Kremer HP, Sinke RJ, Tijssen MA, de Koning TJ: Ramsay Hunt syndrome: clinical characterization of progressive myoclonus ataxia caused by GOSR2 mutation. *Movement disorders : official journal of the Movement Disorder Society* 2014;29:139-143.
- 141 Kurth I, Pamminger T, Hennings JC, Soehendra D, Huebner AK, Roththier A, Baets J, Senderek J, Topaloglu H, Farrell SA, Nurnberg G, Nurnberg P, De Jonghe P, Gal A, Kaether C, Timmerman V, Hubner CA: Mutations in FAM134B, encoding a newly identified Golgi protein, cause severe sensory and autonomic neuropathy. *Nat Genet* 2009;41:1179-1181.
- 142 Thoenes M, Zimmermann U, Ebermann I, Ptok M, Lewis MA, Thiele H, Morlot S, Hess MM, Gal A, Eisenberger T, Bergmann C, Nurnberg G, Nurnberg P, Steel KP, Knipper M, Bolz HJ: OSBPL2 encodes a protein of inner and outer hair cell stereocilia and is mutated in autosomal dominant hearing loss (DFNA67). *Orphanet journal of rare diseases* 2015;10:15.
- 143 Xing G, Yao J, Wu B, Liu T, Wei Q, Liu C, Lu Y, Chen Z, Zheng H, Yang X, Cao X: Identification of OSBPL2 as a novel candidate gene for progressive nonsyndromic hearing loss by whole-exome sequencing. *Genetics in medicine : official journal of the American College of Medical Genetics* 2015;17:210-218.
- 144 Ammann S, Schulz A, Krageloh-Mann I, Dieckmann NM, Niethammer K, Fuchs S, Eckl KM, Plank R, Werner R, Altmuller J, Thiele H, Nurnberg P, Bank J, Strauss A, von Bernuth H, Zur Stadt U, Grieve S, Griffiths GM, Lehmberg K, Hennies HC, Ehl S: Mutations in AP3D1 associated with immunodeficiency and seizures define a new type of Hermansky-Pudlak syndrome. *Blood* 2016;127:997-1006.
- 145 Soong BW, Morrison PJ: Spinocerebellar ataxias. *Handbook of clinical neurology* 2018;155:143-174.
- 146 Edvardson S, Yi JK, J alas C, Xu R, Webb BD, Snider J, Fedick A, Kleinman E, Treff NR, Mao C, Elpeleg O: Deficiency of the alkaline ceramidase ACER3 manifests in early childhood by progressive leukodystrophy. *J Med Genet* 2016;53:389-396.
- 147 Inloes JM, Hsu KL, Dix MM, Viader A, Masuda K, Takei T, Wood MR, Cravatt BF: The hereditary spastic paraplegia-related enzyme DDHD2 is a principal brain triglyceride lipase. *Proc Natl Acad Sci U S A* 2014;111:14924-14929.

- 148 Schuurs-Hoeijmakers JH, Geraghty MT, Kamsteeg EJ, Ben-Salem S, de Bot ST, Nijhof B, van de V, II, van der Graaf M, Nobau AC, Otte-Holler I, Vermeer S, Smith AC, Humphreys P, Schwartzentruber J, Consortium FC, Ali BR, Al-Yahyaee SA, Tariq S, Pramathan T, Bayoumi R, Kremer HP, van de Warrenburg BP, van den Akker WM, Gilissen C, Veltman JA, Janssen IM, Vulto-van Silfhout AT, van der Velde-Visser S, Lefeber DJ, Diekstra A, Erasmus CE, Willemsen MA, Vissers LE, Lammens M, van Bokhoven H, Brunner HG, Wevers RA, Schenck A, Al-Gazali L, de Vries BB, de Brouwer AP: Mutations in DDHD2, encoding an intracellular phospholipase A(1), cause a recessive form of complex hereditary spastic paraplegia. *Am J Hum Genet* 2012;91:1073-1081.
- 149 Hansen L, Tawamie H, Murakami Y, Mang Y, ur Rehman S, Buchert R, Schaffer S, Muhammad S, Bak M, Nothen MM, Bennett EP, Maeda Y, Aigner M, Reis A, Kinoshita T, Tommerup N, Baig SM, Abou Jamra R: Hypomorphic mutations in PGAP2, encoding a GPI-anchor-remodeling protein, cause autosomal-recessive intellectual disability. *Am J Hum Genet* 2013;92:575-583.
- 150 Howard MF, Murakami Y, Pagnamenta AT, Daumer-Haas C, Fischer B, Hecht J, Keays DA, Knight SJ, Kolsch U, Kruger U, Leiz S, Maeda Y, Mitchell D, Mundlos S, Phillips JA, 3rd, Robinson PN, Kini U, Taylor JC, Horn D, Kinoshita T, Krawitz PM: Mutations in PGAP3 impair GPI-anchor maturation, causing a subtype of hyperphosphatasia with mental retardation. *Am J Hum Genet* 2014;94:278-287.
- 151 Krawitz PM, Murakami Y, Riess A, Hietala M, Kruger U, Zhu N, Kinoshita T, Mundlos S, Hecht J, Robinson PN, Horn D: PGAP2 mutations, affecting the GPI-anchor-synthesis pathway, cause hyperphosphatasia with mental retardation syndrome. *Am J Hum Genet* 2013;92:584-589.
- 152 Naseer MI, Rasool M, Jan MM, Chaudhary AG, Pushparaj PN, Abuzenadah AM, Al-Qahtani MH: A novel mutation in PGAP2 gene causes developmental delay, intellectual disability, epilepsy and microcephaly in consanguineous Saudi family. *Journal of the neurological sciences* 2016;371:121-125.
- 153 Perez Y, Wormser O, Sadaka Y, Birk R, Narkis G, Birk OS: A Rare Variant in PGAP2 Causes Autosomal Recessive Hyperphosphatasia with Mental Retardation Syndrome, with a Mild Phenotype in Heterozygous Carriers. *BioMed research international* 2017;2017:3470234.
- 154 Bosch DG, Boonstra FN, Kinoshita T, Jhangiani S, de Ligt J, Cremers FP, Lupski JR, Murakami Y, de Vries BB: Cerebral visual impairment and intellectual disability caused by PGAP1 variants. *Eur J Hum Genet* 2015;23:1689-1693.
- 155 Murakami Y, Tawamie H, Maeda Y, Buttner C, Buchert R, Radwan F, Schaffer S, Sticht H, Aigner M, Reis A, Kinoshita T, Jamra RA: Null mutation in PGAP1 impairing Gpi-anchor maturation in patients with intellectual disability and encephalopathy. *PLoS Genet* 2014;10:e1004320.
- 156 Schachter H, Jaeken J: Carbohydrate-deficient glycoprotein syndrome type II. *Biochim Biophys Acta* 1999;1455:179-192.
- 157 Hansske B, Thiel C, Lubke T, Hasilik M, Honing S, Peters V, Heidemann PH, Hoffmann GF, Berger EG, von Figura K, Korner C: Deficiency of UDP-galactose:N-acetylglucosamine beta-1,4-galactosyltransferase I causes the congenital disorder of glycosylation type IIId. *J Clin Invest* 2002;109:725-733.
- 158 Bielas SL, Silhavy JL, Brancati F, Kisseleva MV, Al-Gazali L, Sztriha L, Bayoumi RA, Zaki MS, Abdel-Aleem A, Rosti RO, Kayserili H, Swistun D, Scott LC, Bertini E, Boltshauser E, Fazzi E, Travaglini L, Field SJ, Gayral S, Jacoby M, Schurmans S, Dallapiccola B, Majerus PW, Valente EM, Gleeson JG: Mutations in INPP5E, encoding inositol polyphosphate-5-phosphatase E, link phosphatidyl inositol signaling to the ciliopathies. *Nat Genet* 2009;41:1032-1036.
- 159 Jacoby M, Cox JJ, Gayral S, Hampshire DJ, Ayub M, Blockmans M, Pernot E, Kisseleva MV, Compere P, Schiffmann SN, Gergely F, Riley JH, Perez-Morga D, Woods CG, Schurmans S: INPP5E mutations cause primary cilium signaling defects, ciliary instability and ciliopathies in human and mouse. *Nat Genet* 2009;41:1027-1031.
- 160 Bandmann O, Weiss KH, Kaler SG: Wilson's disease and other neurological copper disorders. *The Lancet Neurology* 2015;14:103-113.
- 161 Lowe M: Structural organization of the Golgi apparatus. *Curr Opin Cell Biol* 2011;23:85-93.
- 162 Wei JH, Seemann J: Unraveling the Golgi ribbon. *Traffic* 2010;11:1391-1400.
- 163 Short B, Haas A, Barr FA: Golgins and GTPases, giving identity and structure to the Golgi apparatus. *Biochim Biophys Acta* 2005;1744:383-395.
- 164 Gosavi P, Gleeson PA: The Function of the Golgi Ribbon Structure - An Enduring Mystery Unfolds! *BioEssays : news and reviews in molecular, cellular and developmental biology* 2017;39

- 165 Ramirez IB, Lowe M: Golgins and GRASPs: holding the Golgi together. *Seminars in cell & developmental biology* 2009;20:770-779.
- 166 Opdam FJ, Echard A, Croes HJ, van den Hurk JA, van de Vorstenbosch RA, Ginsel LA, Goud B, Franssen JA: The small GTPase Rab6B, a novel Rab6 subfamily member, is cell-type specifically expressed and localised to the Golgi apparatus. *J Cell Sci* 2000;113 (Pt 15):2725-2735.
- 167 Young J, Menetrey J, Goud B: RAB6C is a retrogene that encodes a centrosomal protein involved in cell cycle progression. *Journal of molecular biology* 2010;397:69-88.
- 168 Kodani A, Kristensen I, Huang L, Sutterlin C: GM130-dependent control of Cdc42 activity at the Golgi regulates centrosome organization. *Mol Biol Cell* 2009;20:1192-1200.
- 169 Kodani A, Sutterlin C: The Golgi protein GM130 regulates centrosome morphology and function. *Mol Biol Cell* 2008;19:745-753.
- 170 Preisinger C, Short B, De Corte V, Bruyneel E, Haas A, Kopajtich R, Gettemans J, Barr FA: YSK1 is activated by the Golgi matrix protein GM130 and plays a role in cell migration through its substrate 14-3-3zeta. *The Journal of cell biology* 2004;164:1009-1020.
- 171 Rivero S, Cardenas J, Bornens M, Rios RM: Microtubule nucleation at the cis-side of the Golgi apparatus requires AKAP450 and GM130. *EMBO J* 2009;28:1016-1028.
- 172 Huang W, She L, Chang XY, Yang RR, Wang L, Ji HB, Jiao JW, Poo MM: Protein kinase LKB1 regulates polarized dendrite formation of adult hippocampal newborn neurons. *Proc Natl Acad Sci U S A* 2014;111:469-474.
- 173 Bisel B, Wang Y, Wei JH, Xiang Y, Tang D, Miron-Mendoza M, Yoshimura S, Nakamura N, Seemann J: ERK regulates Golgi and centrosome orientation towards the leading edge through GRASP65. *The Journal of cell biology* 2008;182:837-843.
- 174 Liu S, Storrie B: How Rab proteins determine Golgi structure. *International review of cell and molecular biology* 2015;315:1-22.
- 175 Sutterlin C, Colanzi A: The Golgi and the centrosome: building a functional partnership. *The Journal of cell biology* 2010;188:621-628.
- 176 Colanzi A, Corda D: Mitosis controls the Golgi and the Golgi controls mitosis. *Curr Opin Cell Biol* 2007;19:386-393.
- 177 Colanzi A, Sutterlin C: Signaling at the Golgi during mitosis. *Methods in cell biology* 2013;118:383-400.
- 178 Corda D, Barretta ML, Cervigni RI, Colanzi A: Golgi complex fragmentation in G2/M transition: An organelle-based cell-cycle checkpoint. *IUBMB life* 2012;64:661-670.
- 179 Cervigni RI, Barretta ML, Persico A, Corda D, Colanzi A: The role of Aurora-A kinase in the Golgi-dependent control of mitotic entry. *Bioarchitecture* 2011;1:61-65.
- 180 Arai Y, Taverna E: Neural Progenitor Cell Polarity and Cortical Development. *Frontiers in cellular neuroscience* 2017;11:384.
- 181 Zhou Y, Atkins JB, Rompani SB, Bancescu DL, Petersen PH, Tang H, Zou K, Stewart SB, Zhong W: The mammalian Golgi regulates numb signaling in asymmetric cell division by releasing ACBD3 during mitosis. *Cell* 2007;129:163-178.
- 182 Taniguchi M, Yoshida H: TFE3, HSP47, and CREB3 Pathways of the Mammalian Golgi Stress Response. *Cell structure and function* 2017;42:27-36.
- 183 Ge L, Wilz L, Schekman R: Biogenesis of autophagosomal precursors for LC3 lipidation from the ER-Golgi intermediate compartment. *Autophagy* 2015;11:2372-2374.
- 184 Lamb CA, Yoshimori T, Tooze SA: The autophagosome: origins unknown, biogenesis complex. *Nature reviews Molecular cell biology* 2013;14:759-774.
- 185 Fernandez-Fernandez MR, Ruiz-Garcia D, Martin-Solana E, Chichon FJ, Carrascosa JL, Fernandez JJ: 3D electron tomography of brain tissue unveils distinct Golgi structures that sequester cytoplasmic contents in neurons. *J Cell Sci* 2017;130:83-89.
- 186 Geng J, Klionsky DJ: The Golgi as a potential membrane source for autophagy. *Autophagy* 2010;6:950-951.
- 187 Itoh T, Fujita N, Kanno E, Yamamoto A, Yoshimori T, Fukuda M: Golgi-resident small GTPase Rab33B interacts with Atg16L and modulates autophagosome formation. *Mol Biol Cell* 2008;19:2916-2925.
- 188 Longatti A, Lamb CA, Razi M, Yoshimura S, Barr FA, Tooze SA: TBC1D14 regulates autophagosome formation via Rab11- and ULK1-positive recycling endosomes. *The Journal of cell biology* 2012;197:659-675.

- 189 Oda S, Nozawa T, Nozawa-Minowa A, Tanaka M, Aikawa C, Harada H, Nakagawa I: Golgi-Resident GTPase Rab30 Promotes the Biogenesis of Pathogen-Containing Autophagosomes. *PLoS One* 2016;11:e0147061.
- 190 Wen H, Zhan L, Chen S, Long L, Xu E: Rab7 may be a novel therapeutic target for neurologic diseases as a key regulator in autophagy. *J Neurosci Res* 2017
- 191 Reggiori F, Ungermann C: Autophagosome Maturation and Fusion. *Journal of molecular biology* 2017;429:486-496.
- 192 He C, Levine B: The Beclin 1 interactome. *Curr Opin Cell Biol* 2010;22:140-149.
- 193 He S, Ni D, Ma B, Lee JH, Zhang T, Ghosalli I, Pirooz SD, Zhao Z, Bharatham N, Li B, Oh S, Lee WH, Takahashi Y, Wang HG, Minassian A, Feng P, Deretic V, Pepperkok R, Tagaya M, Yoon HS, Liang C: PtdIns(3)P-bound UVRAG coordinates Golgi-ER retrograde and Atg9 transport by differential interactions with the ER tether and the beclin 1 complex. *Nat Cell Biol* 2013;15:1206-1219.
- 194 Feng Y, Klionsky DJ: Autophagic membrane delivery through ATG9. *Cell research* 2017;27:161-162.
- 195 Young AR, Chan EY, Hu XW, Kochl R, Crawshaw SG, High S, Hailey DW, Lippincott-Schwartz J, Tooze SA: Starvation and ULK1-dependent cycling of mammalian Atg9 between the TGN and endosomes. *J Cell Sci* 2006;119:3888-3900.
- 196 Guo Y, Chang C, Huang R, Liu B, Bao L, Liu W: AP1 is essential for generation of autophagosomes from the trans-Golgi network. *J Cell Sci* 2012;125:1706-1715.
- 197 Mattera R, Park SY, De Pace R, Guardia CM, Bonifacino JS: AP-4 mediates export of ATG9A from the trans-Golgi network to promote autophagosome formation. *Proc Natl Acad Sci U S A* 2017;114:E10697-E10706.
- 198 Ayala I, Colanzi A: Alterations of Golgi organization in Alzheimer's disease: A cause or a consequence? *Tissue & cell* 2017;49:133-140.
- 199 Gonatas NK, Stieber A, Gonatas JO: Fragmentation of the Golgi apparatus in neurodegenerative diseases and cell death. *Journal of the neurological sciences* 2006;246:21-30.
- 200 Sundaramoorthy V, Sultana JM, Atkin JD: Golgi fragmentation in amyotrophic lateral sclerosis, an overview of possible triggers and consequences. *Frontiers in neuroscience* 2015;9:400.
- 201 Hicks SW, Machamer CE: Golgi structure in stress sensing and apoptosis. *Biochim Biophys Acta* 2005;1744:406-414.
- 202 Hicks SW, Machamer CE: The NH2-terminal domain of Golgin-160 contains both Golgi and nuclear targeting information. *J Biol Chem* 2002;277:35833-35839.
- 203 Mukherjee S, Shields D: Nuclear import is required for the pro-apoptotic function of the Golgi protein p115. *J Biol Chem* 2009;284:1709-1717.
- 204 Herrup K: Post-mitotic role of the cell cycle machinery. *Curr Opin Cell Biol* 2013;25:711-716.

Legend to Figure 1: Temporal relationship between major stages of central nervous system development and various physiological functions of the Golgi apparatus

Schematic representation summarizing some of the physiological functions of the Golgi apparatus (GA) proteins (upper section) and major developmental processes of the central nervous system in which these proteins are involved during embryonic/fetal and postnatal life (lower section). Proteins involved in the maintenance of GA structure, integrity and position are required throughout life, as are those involved in the biosynthesis and modification of certain lipids and most proteins. However, the need for other GA functions increases periodically, and proteins involved in these functions may not play a role throughout life or may switch to other roles depending on the stage of the lifespan. For example, during neurogenesis and gliogenesis, when mitotic activity predominates, GA proteins involved in cell cycle regulation (yellow) would be expected to play a major role, and defects in these proteins would have maximum impact and lead to disorders reflecting a lack of neurons and glia. At later stages, other functions predominate, such as cellular polarity and microtubule organization (orange; particularly important for migration and morphogenesis, including the establishment and maturation of the axon and dendritic arbor), apoptosis (violet; crucial for the programmed death of the large excess of neurons produced), autophagy (pink; necessary to remodel the cell but also important in maintenance and repair throughout the lifespan, when it is involved in neurodegenerative processes) and secretory and membrane trafficking (blue; essential for the huge expansion of the cell membrane and secretory activity during synaptogenesis in neurons, branching of astrocytes and myelination by oligodendrocytes, but also necessary for neuronal and glial function throughout the lifespan). NB: the timeline of some of the processes described, for example neurogenesis and myelination, is still subject to debate; some processes involve two or more GA functions simultaneously.